https://bordet.makemeweb.dev/fr/insights-inflammatory-priming-mesenchymal-stromal-cells-functional-biological-impacts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/insights-inflammatory-priming-mesenchymal-stromal-cells-functional-biological-impacts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/outcome-and-prognostic-factors-110-consecutive-patients-primary-uterine-leiomyosarcoma-rare-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/outcome-and-prognostic-factors-110-consecutive-patients-primary-uterine-leiomyosarcoma-rare-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/outcome-and-prognostic-factors-110-consecutive-patients-primary-uterine-leiomyosarcoma-rare-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/distinctive-desmoplastic-3d-morphology-associated-brafv600e-papillary-thyroid-cancers 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/distinctive-desmoplastic-3d-morphology-associated-brafv600e-papillary-thyroid-cancers 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/distinctive-desmoplastic-3d-morphology-associated-brafv600e-papillary-thyroid-cancers 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sequential-tumor-directed-and-lobar-radioembolization-major-hepatectomy-hepatocellular-carcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/sequential-tumor-directed-and-lobar-radioembolization-major-hepatectomy-hepatocellular-carcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/sequential-tumor-directed-and-lobar-radioembolization-major-hepatectomy-hepatocellular-carcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/how-reliable-are-available-safety-data-hormonal-stimulation-fertility-preservation-young-women 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/how-reliable-are-available-safety-data-hormonal-stimulation-fertility-preservation-young-women 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/how-reliable-are-available-safety-data-hormonal-stimulation-fertility-preservation-young-women 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/aldehyde-dehydrogenase-activity-adipose-tissue-isolation-and-gene-expression-profile-distinct-sub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/aldehyde-dehydrogenase-activity-adipose-tissue-isolation-and-gene-expression-profile-distinct-sub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/aldehyde-dehydrogenase-activity-adipose-tissue-isolation-and-gene-expression-profile-distinct-sub 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/editorial-les-revues-predatrices 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-les-revues-predatrices 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-les-revues-predatrices 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-de-la-diminution-du-taux-en-ldl-c-sur-les-complications-vasculaires-majeures-15092017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-de-la-diminution-du-taux-en-ldl-c-sur-les-complications-vasculaires-majeures-15092017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-de-la-diminution-du-taux-en-ldl-c-sur-les-complications-vasculaires-majeures-15092017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/editorial-revue-sur-les-statines-dans-lancet-qu-en-penser 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-revue-sur-les-statines-dans-lancet-qu-en-penser 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-revue-sur-les-statines-dans-lancet-qu-en-penser 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/quel-suivi-apres-traitement-chirurgical-d-un-cancer-colorectal-non-metastatique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quel-suivi-apres-traitement-chirurgical-d-un-cancer-colorectal-non-metastatique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quel-suivi-apres-traitement-chirurgical-d-un-cancer-colorectal-non-metastatique 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/un-taux-accru-de-cholesterol-transporte-par-des-ldl-n-est-pas-associe-une-mortalite-globale-et 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/un-taux-accru-de-cholesterol-transporte-par-des-ldl-n-est-pas-associe-une-mortalite-globale-et 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/un-taux-accru-de-cholesterol-transporte-par-des-ldl-n-est-pas-associe-une-mortalite-globale-et 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/modele-de-population-risque-de-cancer-bronchique-en-vue-d-un-depistage-analyses-breves-1542017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/modele-de-population-risque-de-cancer-bronchique-en-vue-d-un-depistage-analyses-breves-1542017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/modele-de-population-risque-de-cancer-bronchique-en-vue-d-un-depistage-analyses-breves-1542017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/place-des-antibiotiques-dans-le-traitement-de-la-rhinosinusite-chronique-analyse 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/place-des-antibiotiques-dans-le-traitement-de-la-rhinosinusite-chronique-analyse 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/place-des-antibiotiques-dans-le-traitement-de-la-rhinosinusite-chronique-analyse 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/contraceptifs-oraux-oestroprogestatifs-combines-risque-thromboembolique-veineux-et-arteriel-accru 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/contraceptifs-oraux-oestroprogestatifs-combines-risque-thromboembolique-veineux-et-arteriel-accru 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/contraceptifs-oraux-oestroprogestatifs-combines-risque-thromboembolique-veineux-et-arteriel-accru 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/place-des-veinotropes-dans-le-traitement-de-l-insuffisance-veineuse-chronique-analyse-longue 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/place-des-veinotropes-dans-le-traitement-de-l-insuffisance-veineuse-chronique-analyse-longue 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/place-des-veinotropes-dans-le-traitement-de-l-insuffisance-veineuse-chronique-analyse-longue 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/les-patients-avec-indice-de-performance-superieur-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/les-patients-avec-indice-de-performance-superieur-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/les-patients-avec-indice-de-performance-superieur-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/les-patients-avec-indice-de-performance-superieur-1-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/les-patients-avec-indice-de-performance-superieur-1-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/les-patients-avec-indice-de-performance-superieur-1-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multidisciplinary-questions-thoracic-oncology-team-experience-serie-6-edited-j-p-sculier 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multidisciplinary-questions-thoracic-oncology-team-experience-serie-6-edited-j-p-sculier 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multidisciplinary-questions-thoracic-oncology-team-experience-serie-6-edited-j-p-sculier 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-des-effets-de-l-activite-physique-sur-le-systeme-lymphatique-de-patients-avec 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-des-effets-de-l-activite-physique-sur-le-systeme-lymphatique-de-patients-avec 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-des-effets-de-l-activite-physique-sur-le-systeme-lymphatique-de-patients-avec 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/strategies-and-technical-challenges-imaging-oligometastatic-disease-recommendations-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/strategies-and-technical-challenges-imaging-oligometastatic-disease-recommendations-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/strategies-and-technical-challenges-imaging-oligometastatic-disease-recommendations-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-efficacy-anti-programmed-death-1-antibodies-patients-cancer-and-pre-existing-autoimmune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-efficacy-anti-programmed-death-1-antibodies-patients-cancer-and-pre-existing-autoimmune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-efficacy-anti-programmed-death-1-antibodies-patients-cancer-and-pre-existing-autoimmune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/supportive-care-era-immunotherapies-advanced-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/supportive-care-era-immunotherapies-advanced-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/supportive-care-era-immunotherapies-advanced-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/transatlantic-perspective-integration-immuno-oncology-prognostic-and-predictive-biomarkers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/transatlantic-perspective-integration-immuno-oncology-prognostic-and-predictive-biomarkers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/transatlantic-perspective-integration-immuno-oncology-prognostic-and-predictive-biomarkers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/response 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/response 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/response 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immuno-biological-comparison-hepatic-stellate-cells-reverted-and-activated-state 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immuno-biological-comparison-hepatic-stellate-cells-reverted-and-activated-state 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immuno-biological-comparison-hepatic-stellate-cells-reverted-and-activated-state 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/ongoing-unmet-needs-treating-estrogen-receptor-positiveher2-negative-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ongoing-unmet-needs-treating-estrogen-receptor-positiveher2-negative-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ongoing-unmet-needs-treating-estrogen-receptor-positiveher2-negative-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/isolation-and-characterization-mesenchymal-stromal-cells-based-aldehyde-dehydrogenase-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/isolation-and-characterization-mesenchymal-stromal-cells-based-aldehyde-dehydrogenase-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/isolation-and-characterization-mesenchymal-stromal-cells-based-aldehyde-dehydrogenase-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prima-1-and-prima-1-metapr-246-mutantwild-type-p53-reactivation-unexpected-mechanisms-underlying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prima-1-and-prima-1-metapr-246-mutantwild-type-p53-reactivation-unexpected-mechanisms-underlying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prima-1-and-prima-1-metapr-246-mutantwild-type-p53-reactivation-unexpected-mechanisms-underlying 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/network-science-clinical-trials-patient-centered-approach 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/network-science-clinical-trials-patient-centered-approach 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/network-science-clinical-trials-patient-centered-approach 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/can-we-omit-radiotherapy-case-brain-metastases-patients-mutant-egfr-lung-adenocarcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/can-we-omit-radiotherapy-case-brain-metastases-patients-mutant-egfr-lung-adenocarcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/can-we-omit-radiotherapy-case-brain-metastases-patients-mutant-egfr-lung-adenocarcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/comments-sentinel-lymph-node-mapping-isosulfan-blue-or-indocyanine-green-colon-cancer-shows 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comments-sentinel-lymph-node-mapping-isosulfan-blue-or-indocyanine-green-colon-cancer-shows 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comments-sentinel-lymph-node-mapping-isosulfan-blue-or-indocyanine-green-colon-cancer-shows 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/choice-chemotherapy-regimen-early-her2-positive-breast-cancer-elderly-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/choice-chemotherapy-regimen-early-her2-positive-breast-cancer-elderly-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/choice-chemotherapy-regimen-early-her2-positive-breast-cancer-elderly-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunohematology-mesenchymal-stromal-cell-based-therapy-research-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immunohematology-mesenchymal-stromal-cell-based-therapy-research-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immunohematology-mesenchymal-stromal-cell-based-therapy-research-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cardiac-biomarkers-early-detection-and-prediction-trastuzumab-andor-lapatinib-induced 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/cardiac-biomarkers-early-detection-and-prediction-trastuzumab-andor-lapatinib-induced 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/cardiac-biomarkers-early-detection-and-prediction-trastuzumab-andor-lapatinib-induced 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/quelques-reflexions-sur-partage-et-consideration-pour-autrui 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quelques-reflexions-sur-partage-et-consideration-pour-autrui 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quelques-reflexions-sur-partage-et-consideration-pour-autrui 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/religious-and-cultural-aspects-organ-transplantation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/religious-and-cultural-aspects-organ-transplantation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/religious-and-cultural-aspects-organ-transplantation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/galectins-and-carcinogenesis-their-role-head-and-neck-carcinomas-and-thyroid-carcinomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/galectins-and-carcinogenesis-their-role-head-and-neck-carcinomas-and-thyroid-carcinomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/galectins-and-carcinogenesis-their-role-head-and-neck-carcinomas-and-thyroid-carcinomas 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/use-breast-imaging-predicting-response-neoadjuvant-lapatinib-trastuzumab-and-their-combination-her2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/use-breast-imaging-predicting-response-neoadjuvant-lapatinib-trastuzumab-and-their-combination-her2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/use-breast-imaging-predicting-response-neoadjuvant-lapatinib-trastuzumab-and-their-combination-her2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/euthanasie-et-don-d-organes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/euthanasie-et-don-d-organes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/euthanasie-et-don-d-organes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/indocyanine-green-fluorescence-guided-sentinel-lymph-node-identification-urologic-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/indocyanine-green-fluorescence-guided-sentinel-lymph-node-identification-urologic-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/indocyanine-green-fluorescence-guided-sentinel-lymph-node-identification-urologic-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-stage-iii-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-stage-iii-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-stage-iii-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/use-alternative-donors-allogeneic-haematopoietic-cell-transplantation-lymphoid-neoplasms-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/use-alternative-donors-allogeneic-haematopoietic-cell-transplantation-lymphoid-neoplasms-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/use-alternative-donors-allogeneic-haematopoietic-cell-transplantation-lymphoid-neoplasms-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/steps-forward-cancer-precision-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/steps-forward-cancer-precision-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/steps-forward-cancer-precision-medicine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/targeting-immune-checkpoints-breast-cancer-update-early-results 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/targeting-immune-checkpoints-breast-cancer-update-early-results 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/targeting-immune-checkpoints-breast-cancer-update-early-results 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/allogeneic-haematopoietic-cell-transplantation-indolent-lymphomas-guidelines-francophone-society 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/allogeneic-haematopoietic-cell-transplantation-indolent-lymphomas-guidelines-francophone-society 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/allogeneic-haematopoietic-cell-transplantation-indolent-lymphomas-guidelines-francophone-society 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/allogeneic-hematopoietic-cell-transplantation-hodgkin-s-disease-mantle-cell-lymphoma-and-other-rare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/allogeneic-hematopoietic-cell-transplantation-hodgkin-s-disease-mantle-cell-lymphoma-and-other-rare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/allogeneic-hematopoietic-cell-transplantation-hodgkin-s-disease-mantle-cell-lymphoma-and-other-rare 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-significance-cd73-triple-negative-breast-cancer-multiplex-analysis-phase-iii-clinical 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-significance-cd73-triple-negative-breast-cancer-multiplex-analysis-phase-iii-clinical 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-significance-cd73-triple-negative-breast-cancer-multiplex-analysis-phase-iii-clinical 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/effect-adjuvant-chemotherapy-symptom-burden-and-quality-life-over-time-preliminary-prospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-adjuvant-chemotherapy-symptom-burden-and-quality-life-over-time-preliminary-prospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-adjuvant-chemotherapy-symptom-burden-and-quality-life-over-time-preliminary-prospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/allogeneic-haematopoietic-cell-transplantation-diffuse-large-b-cell-lymphoma-guidelines-francophone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/allogeneic-haematopoietic-cell-transplantation-diffuse-large-b-cell-lymphoma-guidelines-francophone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/allogeneic-haematopoietic-cell-transplantation-diffuse-large-b-cell-lymphoma-guidelines-francophone 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-re-aligning-asco-and-esmo-clinical-benefit-frameworks-or-modern-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-re-aligning-asco-and-esmo-clinical-benefit-frameworks-or-modern-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-re-aligning-asco-and-esmo-clinical-benefit-frameworks-or-modern-cancer-therapies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunomodulatory-effects-foreskin-mesenchymal-stromal-cells-fsk-mscs-natural-killer-nk-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immunomodulatory-effects-foreskin-mesenchymal-stromal-cells-fsk-mscs-natural-killer-nk-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immunomodulatory-effects-foreskin-mesenchymal-stromal-cells-fsk-mscs-natural-killer-nk-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/critical-features-and-challenges-associated-imaging-patients-undergoing-cancer-immunotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/critical-features-and-challenges-associated-imaging-patients-undergoing-cancer-immunotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/critical-features-and-challenges-associated-imaging-patients-undergoing-cancer-immunotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/18e-journee-annuelle-d-oncologie-thoracique-jaot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/18e-journee-annuelle-d-oncologie-thoracique-jaot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/18e-journee-annuelle-d-oncologie-thoracique-jaot 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-chemotherapy-induced-neutropenia-cin-and-febrile-neutropenia-fn-cancer-treatment-outcomes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-chemotherapy-induced-neutropenia-cin-and-febrile-neutropenia-fn-cancer-treatment-outcomes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-chemotherapy-induced-neutropenia-cin-and-febrile-neutropenia-fn-cancer-treatment-outcomes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-laboratoire-de-medecine-factuelle-labmef-de-la-faculte-de-medecine-de-l-ulb 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-laboratoire-de-medecine-factuelle-labmef-de-la-faculte-de-medecine-de-l-ulb 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-laboratoire-de-medecine-factuelle-labmef-de-la-faculte-de-medecine-de-l-ulb 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immune-checkpoint-molecules-tumor-infiltrating-lymphocytes-and-their-association-tertiary-lymphoid 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-checkpoint-molecules-tumor-infiltrating-lymphocytes-and-their-association-tertiary-lymphoid 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-checkpoint-molecules-tumor-infiltrating-lymphocytes-and-their-association-tertiary-lymphoid 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/medecine-et-politique-une-cohabitation-difficile 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/medecine-et-politique-une-cohabitation-difficile 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/medecine-et-politique-une-cohabitation-difficile 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumourmetrics-comprehensive-clinical-solution-standardization-dce-mri-analysis-research-and-routine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumourmetrics-comprehensive-clinical-solution-standardization-dce-mri-analysis-research-and-routine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumourmetrics-comprehensive-clinical-solution-standardization-dce-mri-analysis-research-and-routine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oxidative-stress-and-prostatic-diseases 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oxidative-stress-and-prostatic-diseases 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oxidative-stress-and-prostatic-diseases 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/distribution-clinical-risk-factors-fracture-brussels-cohort-postmenopausal-women-frisbee-study-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/distribution-clinical-risk-factors-fracture-brussels-cohort-postmenopausal-women-frisbee-study-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/distribution-clinical-risk-factors-fracture-brussels-cohort-postmenopausal-women-frisbee-study-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/extended-adjuvant-intermittent-letrozole-versus-continuous-letrozole-postmenopausal-women-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/extended-adjuvant-intermittent-letrozole-versus-continuous-letrozole-postmenopausal-women-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/extended-adjuvant-intermittent-letrozole-versus-continuous-letrozole-postmenopausal-women-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/p-stat3-luminal-breast-cancer-integrated-rna-protein-pooled-analysis-and-results-big-2-98-phase-iii 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/p-stat3-luminal-breast-cancer-integrated-rna-protein-pooled-analysis-and-results-big-2-98-phase-iii 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/p-stat3-luminal-breast-cancer-integrated-rna-protein-pooled-analysis-and-results-big-2-98-phase-iii 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/patterns-and-predictors-recurrence-after-open-radical-cystectomy-bladder-cancer-comprehensive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/patterns-and-predictors-recurrence-after-open-radical-cystectomy-bladder-cancer-comprehensive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/patterns-and-predictors-recurrence-after-open-radical-cystectomy-bladder-cancer-comprehensive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/resection-pancreatic-cancer-europe-and-usa-international-large-scale-study-highlighting-large 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/resection-pancreatic-cancer-europe-and-usa-international-large-scale-study-highlighting-large 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/resection-pancreatic-cancer-europe-and-usa-international-large-scale-study-highlighting-large 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/network-meta-analysis-second-line-treatment-metastatic-renal-cell-carcinoma-efficacy-and-safety 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/network-meta-analysis-second-line-treatment-metastatic-renal-cell-carcinoma-efficacy-and-safety 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/network-meta-analysis-second-line-treatment-metastatic-renal-cell-carcinoma-efficacy-and-safety 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/are-concurrent-systematic-cores-needed-time-targeted-biopsy-patients-prior-negative-prostate 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/are-concurrent-systematic-cores-needed-time-targeted-biopsy-patients-prior-negative-prostate 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/are-concurrent-systematic-cores-needed-time-targeted-biopsy-patients-prior-negative-prostate 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/impact-body-mass-index-clinical-outcomes-patients-her2-positive-metastatic-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/impact-body-mass-index-clinical-outcomes-patients-her2-positive-metastatic-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/impact-body-mass-index-clinical-outcomes-patients-her2-positive-metastatic-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/increased-live-births-after-day-5-versus-day-6-transfers-vitrified-warmed-blastocysts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/increased-live-births-after-day-5-versus-day-6-transfers-vitrified-warmed-blastocysts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/increased-live-births-after-day-5-versus-day-6-transfers-vitrified-warmed-blastocysts 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-st-gallen-international-expert-consensus-primary-therapy-early-breast-cancer-2017-point-view 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-st-gallen-international-expert-consensus-primary-therapy-early-breast-cancer-2017-point-view 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-st-gallen-international-expert-consensus-primary-therapy-early-breast-cancer-2017-point-view 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/risk-adverse-events-addition-targeted-agents-endocrine-therapy-patients-hormone-receptor-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/risk-adverse-events-addition-targeted-agents-endocrine-therapy-patients-hormone-receptor-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/risk-adverse-events-addition-targeted-agents-endocrine-therapy-patients-hormone-receptor-positive 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/study-protocol-think-multinational-open-label-phase-i-study-assess-safety-and-clinical-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/study-protocol-think-multinational-open-label-phase-i-study-assess-safety-and-clinical-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/study-protocol-think-multinational-open-label-phase-i-study-assess-safety-and-clinical-activity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-therapy-rectal-cancer-patients-clinical-stage-ii-iii-across-european-countries 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-therapy-rectal-cancer-patients-clinical-stage-ii-iii-across-european-countries 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-therapy-rectal-cancer-patients-clinical-stage-ii-iii-across-european-countries 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/new-drug-combination-strategies-melanoma-current-status-and-future-directions 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/new-drug-combination-strategies-melanoma-current-status-and-future-directions 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/new-drug-combination-strategies-melanoma-current-status-and-future-directions 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/update-tumor-infiltrating-lymphocytes-tils-breast-cancer-including-recommendations-assess-tils 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/update-tumor-infiltrating-lymphocytes-tils-breast-cancer-including-recommendations-assess-tils 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/update-tumor-infiltrating-lymphocytes-tils-breast-cancer-including-recommendations-assess-tils 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/toxicity-adjustment-esmo-mcbs-diligent-process-data-interpretation-peer-review-far-gestalt 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/toxicity-adjustment-esmo-mcbs-diligent-process-data-interpretation-peer-review-far-gestalt 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/toxicity-adjustment-esmo-mcbs-diligent-process-data-interpretation-peer-review-far-gestalt 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/gene-signature-predict-high-tumour-infiltrating-lymphocytes-after-neoadjuvant-chemotherapy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/gene-signature-predict-high-tumour-infiltrating-lymphocytes-after-neoadjuvant-chemotherapy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/gene-signature-predict-high-tumour-infiltrating-lymphocytes-after-neoadjuvant-chemotherapy-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-male-breast-cancer-results-eortc-10085tbcrcbignabcg-international-male-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-male-breast-cancer-results-eortc-10085tbcrcbignabcg-international-male-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-male-breast-cancer-results-eortc-10085tbcrcbignabcg-international-male-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reproductive-potential-and-performance-fertility-preservation-strategies-brca-mutated-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/reproductive-potential-and-performance-fertility-preservation-strategies-brca-mutated-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/reproductive-potential-and-performance-fertility-preservation-strategies-brca-mutated-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/hepatoid-adenocarcinoma-stomach-challenging-diagnostic-and-therapeutic-disease-through-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hepatoid-adenocarcinoma-stomach-challenging-diagnostic-and-therapeutic-disease-through-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hepatoid-adenocarcinoma-stomach-challenging-diagnostic-and-therapeutic-disease-through-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pd-1-hi-cxcr5-cd4-t-fh-cells-play-defense-cancer-and-offense-arthritis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pd-1-hi-cxcr5-cd4-t-fh-cells-play-defense-cancer-and-offense-arthritis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pd-1-hi-cxcr5-cd4-t-fh-cells-play-defense-cancer-and-offense-arthritis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/charcot-marie-tooth-hereditary-neuropathy-revealed-after-administration-docetaxel-advanced-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/charcot-marie-tooth-hereditary-neuropathy-revealed-after-administration-docetaxel-advanced-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/charcot-marie-tooth-hereditary-neuropathy-revealed-after-administration-docetaxel-advanced-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cdk46-blockade-breast-cancer-current-experience-and-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cdk46-blockade-breast-cancer-current-experience-and-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cdk46-blockade-breast-cancer-current-experience-and-future-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/micronome-mesenchymal-stromal-cells-partially-responsive-inflammation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/micronome-mesenchymal-stromal-cells-partially-responsive-inflammation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/micronome-mesenchymal-stromal-cells-partially-responsive-inflammation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/standardised-generic-validated-approach-stratify-magnitude-clinical-benefit-can-be-anticipated-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/standardised-generic-validated-approach-stratify-magnitude-clinical-benefit-can-be-anticipated-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/standardised-generic-validated-approach-stratify-magnitude-clinical-benefit-can-be-anticipated-anti 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adenoid-cystic-carcinoma-breast-aggressive-presentation-pulmonary-kidney-and-brain-metastases-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adenoid-cystic-carcinoma-breast-aggressive-presentation-pulmonary-kidney-and-brain-metastases-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adenoid-cystic-carcinoma-breast-aggressive-presentation-pulmonary-kidney-and-brain-metastases-case 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-safety-pregnancy-following-breast-cancer-according-estrogen-receptor-status 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/long-term-safety-pregnancy-following-breast-cancer-according-estrogen-receptor-status 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/long-term-safety-pregnancy-following-breast-cancer-according-estrogen-receptor-status 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/detailed-statistical-assessment-characteristics-esmo-magnitude-clinical-benefit-scale-esmo-mcbs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/detailed-statistical-assessment-characteristics-esmo-magnitude-clinical-benefit-scale-esmo-mcbs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/detailed-statistical-assessment-characteristics-esmo-magnitude-clinical-benefit-scale-esmo-mcbs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pharmacologic-measures-prevention-left-ventricular-dysfunction-associated-molecular-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pharmacologic-measures-prevention-left-ventricular-dysfunction-associated-molecular-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pharmacologic-measures-prevention-left-ventricular-dysfunction-associated-molecular-targeted 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/recurrence-dynamics-breast-cancer-according-baseline-body-mass-index 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/recurrence-dynamics-breast-cancer-according-baseline-body-mass-index 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/recurrence-dynamics-breast-cancer-according-baseline-body-mass-index 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/hepatitis-e-virus-hev-seroprevalence-and-hev-rna-detection-subjects-attending-sexually-transmitted 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/hepatitis-e-virus-hev-seroprevalence-and-hev-rna-detection-subjects-attending-sexually-transmitted 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/hepatitis-e-virus-hev-seroprevalence-and-hev-rna-detection-subjects-attending-sexually-transmitted 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/mnk12-inhibition-limits-oncogenicity-and-metastasis-kit-mutant-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/mnk12-inhibition-limits-oncogenicity-and-metastasis-kit-mutant-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/mnk12-inhibition-limits-oncogenicity-and-metastasis-kit-mutant-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prospective-comparison-f-18-choline-petct-scan-versus-axial-mri-detecting-bone-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prospective-comparison-f-18-choline-petct-scan-versus-axial-mri-detecting-bone-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prospective-comparison-f-18-choline-petct-scan-versus-axial-mri-detecting-bone-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/opioid-free-anesthesia-what-about-patient-comfort-prospectiverandomized-controlled-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/opioid-free-anesthesia-what-about-patient-comfort-prospectiverandomized-controlled-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/opioid-free-anesthesia-what-about-patient-comfort-prospectiverandomized-controlled-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-dose-escalation-study-anti-cd70-antibody-argx-110-advanced-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-dose-escalation-study-anti-cd70-antibody-argx-110-advanced-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-dose-escalation-study-anti-cd70-antibody-argx-110-advanced-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-evolution-breast-cancer-metastasis-and-relapse 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-evolution-breast-cancer-metastasis-and-relapse 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-evolution-breast-cancer-metastasis-and-relapse 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-buparlisib-plus-trastuzumab-and-paclitaxel-women-her2-primary-breast-cancer-randomised 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-buparlisib-plus-trastuzumab-and-paclitaxel-women-her2-primary-breast-cancer-randomised 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-buparlisib-plus-trastuzumab-and-paclitaxel-women-her2-primary-breast-cancer-randomised 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/development-multi-dimensional-analysis-patient-outcome-predictions-mdpop-during-medical-encounters 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/development-multi-dimensional-analysis-patient-outcome-predictions-mdpop-during-medical-encounters 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/development-multi-dimensional-analysis-patient-outcome-predictions-mdpop-during-medical-encounters 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/triptorelin-relief-lower-urinary-tract-symptoms-men-advanced-prostate-cancer-results-prospective 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/triptorelin-relief-lower-urinary-tract-symptoms-men-advanced-prostate-cancer-results-prospective 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/triptorelin-relief-lower-urinary-tract-symptoms-men-advanced-prostate-cancer-results-prospective 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-4 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-4 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-4 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-5 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-5 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-5 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/n-acetylcysteine-breaks-resistance-trastuzumab-caused-muc4-overexpression-human-her2-positive-bc 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/n-acetylcysteine-breaks-resistance-trastuzumab-caused-muc4-overexpression-human-her2-positive-bc 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/n-acetylcysteine-breaks-resistance-trastuzumab-caused-muc4-overexpression-human-her2-positive-bc 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/erratum-prolonged-survival-patients-breast-cancer-and-history-brain-metastases-results-preplanned 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/erratum-prolonged-survival-patients-breast-cancer-and-history-brain-metastases-results-preplanned 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/erratum-prolonged-survival-patients-breast-cancer-and-history-brain-metastases-results-preplanned 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pharmacokinetics-and-safety-results-phase-3-randomized-open-label-study-intravenous-posaconazole 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pharmacokinetics-and-safety-results-phase-3-randomized-open-label-study-intravenous-posaconazole 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pharmacokinetics-and-safety-results-phase-3-randomized-open-label-study-intravenous-posaconazole 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-supratentorial-recurrent-low-grade-glioma-multidisciplinary-experience-35-adult-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-supratentorial-recurrent-low-grade-glioma-multidisciplinary-experience-35-adult-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-supratentorial-recurrent-low-grade-glioma-multidisciplinary-experience-35-adult-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/de-escalating-and-escalating-treatments-early-stage-breast-cancer-st-gallen-international-expert-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/de-escalating-and-escalating-treatments-early-stage-breast-cancer-st-gallen-international-expert-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/de-escalating-and-escalating-treatments-early-stage-breast-cancer-st-gallen-international-expert-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cancer-drugs-survival-and-ethics-critical-look-inside 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-drugs-survival-and-ethics-critical-look-inside 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-drugs-survival-and-ethics-critical-look-inside 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neuropathic-pain-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neuropathic-pain-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neuropathic-pain-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/european-cancer-patient-s-bill-rights-update-and-implementation-2016 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/european-cancer-patient-s-bill-rights-update-and-implementation-2016 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/european-cancer-patient-s-bill-rights-update-and-implementation-2016 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/l-editorial-du-redacteur-en-chef-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/l-editorial-du-redacteur-en-chef-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/l-editorial-du-redacteur-en-chef-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tpf-plus-cetuximab-induction-chemotherapy-followed-biochemoradiation-weekly-cetuximab-plus-weekly 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tpf-plus-cetuximab-induction-chemotherapy-followed-biochemoradiation-weekly-cetuximab-plus-weekly 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tpf-plus-cetuximab-induction-chemotherapy-followed-biochemoradiation-weekly-cetuximab-plus-weekly 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunohistochemical-versus-molecular-blueprint-and-mammaprint-subtyping-breast-carcinoma-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/immunohistochemical-versus-molecular-blueprint-and-mammaprint-subtyping-breast-carcinoma-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/immunohistochemical-versus-molecular-blueprint-and-mammaprint-subtyping-breast-carcinoma-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/assessing-tumor-infiltrating-lymphocytes-solid-tumors-practical-review-pathologists-and-proposal 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/assessing-tumor-infiltrating-lymphocytes-solid-tumors-practical-review-pathologists-and-proposal 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/assessing-tumor-infiltrating-lymphocytes-solid-tumors-practical-review-pathologists-and-proposal 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/esmo-magnitude-clinical-benefit-scale-version-11 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/esmo-magnitude-clinical-benefit-scale-version-11 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/esmo-magnitude-clinical-benefit-scale-version-11 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/temporal-changes-thyroid-nodule-volume-lack-effect-paranodular-thyroid-tissue-volume 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/temporal-changes-thyroid-nodule-volume-lack-effect-paranodular-thyroid-tissue-volume 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/temporal-changes-thyroid-nodule-volume-lack-effect-paranodular-thyroid-tissue-volume 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/assessing-tumor-infiltrating-lymphocytes-solid-tumors-practical-review-pathologists-and-proposal-0 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/assessing-tumor-infiltrating-lymphocytes-solid-tumors-practical-review-pathologists-and-proposal-0 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/assessing-tumor-infiltrating-lymphocytes-solid-tumors-practical-review-pathologists-and-proposal-0 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/eano-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow-patients-leptomeningeal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eano-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow-patients-leptomeningeal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eano-esmo-clinical-practice-guidelines-diagnosis-treatment-and-follow-patients-leptomeningeal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/her2-positive-breast-cancer-lost-translation-time-patient-centered-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/her2-positive-breast-cancer-lost-translation-time-patient-centered-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/her2-positive-breast-cancer-lost-translation-time-patient-centered-research 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/contribution-temozolomide-chemotherapy-intramedullary-grade-ii-spinal-cord-astrocytomas-adults-our 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/contribution-temozolomide-chemotherapy-intramedullary-grade-ii-spinal-cord-astrocytomas-adults-our 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/contribution-temozolomide-chemotherapy-intramedullary-grade-ii-spinal-cord-astrocytomas-adults-our 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/male-breast-cancer-finding-way-uncommon-path 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/male-breast-cancer-finding-way-uncommon-path 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/male-breast-cancer-finding-way-uncommon-path 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/inflammatory-stroma-lymphoepithelioma-carcinoma-cervix-immunohistochemical-study-3-cases-and-review 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/inflammatory-stroma-lymphoepithelioma-carcinoma-cervix-immunohistochemical-study-3-cases-and-review 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/inflammatory-stroma-lymphoepithelioma-carcinoma-cervix-immunohistochemical-study-3-cases-and-review 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pain-control-thoracic-oncology 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pain-control-thoracic-oncology 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pain-control-thoracic-oncology 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-iii-randomized-study-comparing-chemotherapy-cisplatin-and-etoposide-etoposide-regimen-without 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-iii-randomized-study-comparing-chemotherapy-cisplatin-and-etoposide-etoposide-regimen-without 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-iii-randomized-study-comparing-chemotherapy-cisplatin-and-etoposide-etoposide-regimen-without 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cd73-promotes-resistance-her2erbb2-antibody-therapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/cd73-promotes-resistance-her2erbb2-antibody-therapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/cd73-promotes-resistance-her2erbb2-antibody-therapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/emerging-treatments-her2-positive-early-stage-breast-cancer-focus-neratinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/emerging-treatments-her2-positive-early-stage-breast-cancer-focus-neratinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/emerging-treatments-her2-positive-early-stage-breast-cancer-focus-neratinib 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fertility-and-pregnancy-issues-brca-mutated-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/fertility-and-pregnancy-issues-brca-mutated-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/fertility-and-pregnancy-issues-brca-mutated-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/societal-challenges-precision-medicine-bringing-order-chaos 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/societal-challenges-precision-medicine-bringing-order-chaos 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/societal-challenges-precision-medicine-bringing-order-chaos 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/characterisation-hla-drb10701-biomarker-lapatinib-induced-liver-toxicity-during-treatment-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterisation-hla-drb10701-biomarker-lapatinib-induced-liver-toxicity-during-treatment-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterisation-hla-drb10701-biomarker-lapatinib-induced-liver-toxicity-during-treatment-early 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/monitoring-molecular-response-adult-t-cell-leukemia-high-throughput-sequencing-analysis-htlv-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/monitoring-molecular-response-adult-t-cell-leukemia-high-throughput-sequencing-analysis-htlv-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/monitoring-molecular-response-adult-t-cell-leukemia-high-throughput-sequencing-analysis-htlv-1 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/legends-urology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/legends-urology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/legends-urology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/icg-fluorescence-imaging-detection-peritoneal-metastases-and-residual-tumoral-scars-locally 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/icg-fluorescence-imaging-detection-peritoneal-metastases-and-residual-tumoral-scars-locally 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/icg-fluorescence-imaging-detection-peritoneal-metastases-and-residual-tumoral-scars-locally 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/patterns-spread-and-prognostic-implications-lung-cancer-metastasis-era-driver-mutations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/patterns-spread-and-prognostic-implications-lung-cancer-metastasis-era-driver-mutations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/patterns-spread-and-prognostic-implications-lung-cancer-metastasis-era-driver-mutations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/gonadotropin-releasing-hormone-analogs-ovarian-function-protection-during-chemotherapy-young-early 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/gonadotropin-releasing-hormone-analogs-ovarian-function-protection-during-chemotherapy-young-early 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/gonadotropin-releasing-hormone-analogs-ovarian-function-protection-during-chemotherapy-young-early 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/challenges-and-perspectives-immunotherapy-hodgkin-lymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/challenges-and-perspectives-immunotherapy-hodgkin-lymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/challenges-and-perspectives-immunotherapy-hodgkin-lymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/agonist-immunotherapy-restores-t-cell-function-following-mek-inhibition-improving-efficacy-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/agonist-immunotherapy-restores-t-cell-function-following-mek-inhibition-improving-efficacy-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/agonist-immunotherapy-restores-t-cell-function-following-mek-inhibition-improving-efficacy-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/combination-galectin-3-ck19-and-hbme-1-immunostaining-improves-diagnosis-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/combination-galectin-3-ck19-and-hbme-1-immunostaining-improves-diagnosis-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/combination-galectin-3-ck19-and-hbme-1-immunostaining-improves-diagnosis-thyroid-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/response-ovarian-granulosa-cell-tumor-everolimus-and-exemestane-after-initial-response-letrozole 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/response-ovarian-granulosa-cell-tumor-everolimus-and-exemestane-after-initial-response-letrozole 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/response-ovarian-granulosa-cell-tumor-everolimus-and-exemestane-after-initial-response-letrozole 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/absence-clinical-cerebellar-syndrome-after-serial-injections-more-20-doses-gadoterate-macrocyclic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/absence-clinical-cerebellar-syndrome-after-serial-injections-more-20-doses-gadoterate-macrocyclic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/absence-clinical-cerebellar-syndrome-after-serial-injections-more-20-doses-gadoterate-macrocyclic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/non-coding-function-tyrp1-mrna-promotes-melanoma-growth 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/non-coding-function-tyrp1-mrna-promotes-melanoma-growth 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/non-coding-function-tyrp1-mrna-promotes-melanoma-growth 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prediction-local-and-metastatic-recurrence-solitary-fibrous-tumor-construction-risk-calculator 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prediction-local-and-metastatic-recurrence-solitary-fibrous-tumor-construction-risk-calculator 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prediction-local-and-metastatic-recurrence-solitary-fibrous-tumor-construction-risk-calculator 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/ere-dependent-transcription-and-cell-proliferation-independency-these-two-processes-mediated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ere-dependent-transcription-and-cell-proliferation-independency-these-two-processes-mediated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ere-dependent-transcription-and-cell-proliferation-independency-these-two-processes-mediated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/transcription-factor-7-2-peroxisome-proliferator-activated-receptor-gamma-coactivator-1-alpha-axis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/transcription-factor-7-2-peroxisome-proliferator-activated-receptor-gamma-coactivator-1-alpha-axis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/transcription-factor-7-2-peroxisome-proliferator-activated-receptor-gamma-coactivator-1-alpha-axis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/determinants-1-year-survival-critically-ill-acute-leukemia-patients-grrr-oh-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/determinants-1-year-survival-critically-ill-acute-leukemia-patients-grrr-oh-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/determinants-1-year-survival-critically-ill-acute-leukemia-patients-grrr-oh-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-macrophage-migration-inhibitory-factor-head-and-neck-cancer-and-novel-therapeutic-targets 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/role-macrophage-migration-inhibitory-factor-head-and-neck-cancer-and-novel-therapeutic-targets 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/role-macrophage-migration-inhibitory-factor-head-and-neck-cancer-and-novel-therapeutic-targets 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/outcome-first-100-nasopharyngeal-cancer-patients-thailand-treated-helical-tomotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/outcome-first-100-nasopharyngeal-cancer-patients-thailand-treated-helical-tomotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/outcome-first-100-nasopharyngeal-cancer-patients-thailand-treated-helical-tomotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/reply-letter-editor-addressing-quality-esmo-mcbs-del-paggio 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-letter-editor-addressing-quality-esmo-mcbs-del-paggio 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-letter-editor-addressing-quality-esmo-mcbs-del-paggio 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rational-therapeutic-choice-older-patients-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/rational-therapeutic-choice-older-patients-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/rational-therapeutic-choice-older-patients-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/anastrozole-versus-tamoxifen-prevention-locoregional-and-contralateral-breast-cancer-postmenopausal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/anastrozole-versus-tamoxifen-prevention-locoregional-and-contralateral-breast-cancer-postmenopausal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/anastrozole-versus-tamoxifen-prevention-locoregional-and-contralateral-breast-cancer-postmenopausal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/midst-revolution-thoracic-oncology-action-plan-phase-ii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/midst-revolution-thoracic-oncology-action-plan-phase-ii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/midst-revolution-thoracic-oncology-action-plan-phase-ii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/les-etudes-de-medecine-un-parcours-du-combattant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/les-etudes-de-medecine-un-parcours-du-combattant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/les-etudes-de-medecine-un-parcours-du-combattant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-mot-du-redacteur-en-chef 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-mot-du-redacteur-en-chef 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-mot-du-redacteur-en-chef 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-changement-dans-la-continuite 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-changement-dans-la-continuite 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-changement-dans-la-continuite 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cancer-des-non-fumeurs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-des-non-fumeurs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-des-non-fumeurs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/l-euthanasie-et-la-gestion-de-fin-de-vie-un-debat-ethique-permanent 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/l-euthanasie-et-la-gestion-de-fin-de-vie-un-debat-ethique-permanent 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/l-euthanasie-et-la-gestion-de-fin-de-vie-un-debat-ethique-permanent 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/dispositifs-intra-uterins-au-levonorgestrel-et-risque-de-cancer-du-sein 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/dispositifs-intra-uterins-au-levonorgestrel-et-risque-de-cancer-du-sein 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/dispositifs-intra-uterins-au-levonorgestrel-et-risque-de-cancer-du-sein 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/les-patients-rapportent-ils-mieux-les-effets-toxiques-subjectifs-de-la-chimiotherapie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/les-patients-rapportent-ils-mieux-les-effets-toxiques-subjectifs-de-la-chimiotherapie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/les-patients-rapportent-ils-mieux-les-effets-toxiques-subjectifs-de-la-chimiotherapie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/y-t-il-un-role-pour-les-nouveaux-anticoagulants-oraux-dans-le-traitement-long-terme-de-l-embolie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/y-t-il-un-role-pour-les-nouveaux-anticoagulants-oraux-dans-le-traitement-long-terme-de-l-embolie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/y-t-il-un-role-pour-les-nouveaux-anticoagulants-oraux-dans-le-traitement-long-terme-de-l-embolie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/soins-intensifs-oncologiques-revue-des-annees-2013-et-2014 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/soins-intensifs-oncologiques-revue-des-annees-2013-et-2014 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/soins-intensifs-oncologiques-revue-des-annees-2013-et-2014 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/opiaces-pour-la-douleur-chronique-non-liee-au-cancer-risque-accru-d-accidents-de-surdosage-avec-les 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/opiaces-pour-la-douleur-chronique-non-liee-au-cancer-risque-accru-d-accidents-de-surdosage-avec-les 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/opiaces-pour-la-douleur-chronique-non-liee-au-cancer-risque-accru-d-accidents-de-surdosage-avec-les 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/analyse-de-tinzaparine-ou-antivitamines-k-pour-le-traitement-d-une-thromboembolie-veineuse-dans-le 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/analyse-de-tinzaparine-ou-antivitamines-k-pour-le-traitement-d-une-thromboembolie-veineuse-dans-le 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/analyse-de-tinzaparine-ou-antivitamines-k-pour-le-traitement-d-une-thromboembolie-veineuse-dans-le 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/16eme-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/16eme-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/16eme-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-de-corticosteroides-dans-le-cancer-de-la-prostate-effet-benefique-ou-nefaste 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/role-de-corticosteroides-dans-le-cancer-de-la-prostate-effet-benefique-ou-nefaste 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/role-de-corticosteroides-dans-le-cancer-de-la-prostate-effet-benefique-ou-nefaste 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/quality-assurance-qa-radiotherapy-how-important-it-icact 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-assurance-qa-radiotherapy-how-important-it-icact 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-assurance-qa-radiotherapy-how-important-it-icact 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/preoperative-assessment-and-intervention-optimizing-outcomes-early-return-urinary-continence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/preoperative-assessment-and-intervention-optimizing-outcomes-early-return-urinary-continence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/preoperative-assessment-and-intervention-optimizing-outcomes-early-return-urinary-continence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/nutrition-et-prevention-du-cancer-changer-les-mentalites 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nutrition-et-prevention-du-cancer-changer-les-mentalites 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nutrition-et-prevention-du-cancer-changer-les-mentalites 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/foreword 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/foreword 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/foreword 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thoracoscopic-talc-pleurodesis-malignant-pleural-effusions-impact-high-frequency-jet-ventilation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracoscopic-talc-pleurodesis-malignant-pleural-effusions-impact-high-frequency-jet-ventilation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracoscopic-talc-pleurodesis-malignant-pleural-effusions-impact-high-frequency-jet-ventilation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/aurora-pilot-study-molecular-screening-patients-advanced-breast-cancer-study-breast-international 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/aurora-pilot-study-molecular-screening-patients-advanced-breast-cancer-study-breast-international 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/aurora-pilot-study-molecular-screening-patients-advanced-breast-cancer-study-breast-international 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-treatment-induced-cardiotoxicity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-treatment-induced-cardiotoxicity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-treatment-induced-cardiotoxicity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/intensive-care-medicine-research-agenda-critically-ill-oncology-and-hematology-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/intensive-care-medicine-research-agenda-critically-ill-oncology-and-hematology-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/intensive-care-medicine-research-agenda-critically-ill-oncology-and-hematology-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/benign-tumors-parotid-gland-retrospective-study-339-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/benign-tumors-parotid-gland-retrospective-study-339-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/benign-tumors-parotid-gland-retrospective-study-339-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/footprint-ageing-stroma-older-patients-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/footprint-ageing-stroma-older-patients-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/footprint-ageing-stroma-older-patients-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/second-wave-immune-checkpoint-inhibitor-tsunami-advance-challenges-and-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/second-wave-immune-checkpoint-inhibitor-tsunami-advance-challenges-and-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/second-wave-immune-checkpoint-inhibitor-tsunami-advance-challenges-and-perspectives 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/how-emerge-conservatism-clinical-research-methodology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/how-emerge-conservatism-clinical-research-methodology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/how-emerge-conservatism-clinical-research-methodology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/complete-genome-sequence-campylobacter-concisus-atcc-33237-t-and-draft-genome-sequences-additional 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/complete-genome-sequence-campylobacter-concisus-atcc-33237-t-and-draft-genome-sequences-additional 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/complete-genome-sequence-campylobacter-concisus-atcc-33237-t-and-draft-genome-sequences-additional 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/dna-methylation-based-immune-response-signature-improves-patient-diagnosis-multiple-cancers 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/dna-methylation-based-immune-response-signature-improves-patient-diagnosis-multiple-cancers 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/dna-methylation-based-immune-response-signature-improves-patient-diagnosis-multiple-cancers 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/identifying-critical-steps-towards-improved-access-innovation-cancer-care-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/identifying-critical-steps-towards-improved-access-innovation-cancer-care-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/identifying-critical-steps-towards-improved-access-innovation-cancer-care-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-impact-tumor-hpv-status-outcome-patients-locally-advanced-unresectable-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-impact-tumor-hpv-status-outcome-patients-locally-advanced-unresectable-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-impact-tumor-hpv-status-outcome-patients-locally-advanced-unresectable-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/communication-about-uncertainty-and-hope-randomized-controlled-trial-assessing-efficacy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/communication-about-uncertainty-and-hope-randomized-controlled-trial-assessing-efficacy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/communication-about-uncertainty-and-hope-randomized-controlled-trial-assessing-efficacy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/htlv-1-induced-leukotriene-b4-secretion-t-cells-promotes-t-cell-recruitment-and-virus-propagation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/htlv-1-induced-leukotriene-b4-secretion-t-cells-promotes-t-cell-recruitment-and-virus-propagation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/htlv-1-induced-leukotriene-b4-secretion-t-cells-promotes-t-cell-recruitment-and-virus-propagation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/supportive-care-patients-undergoing-immunotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/supportive-care-patients-undergoing-immunotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/supportive-care-patients-undergoing-immunotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/le-mot-du-redac-chef-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/le-mot-du-redac-chef-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/le-mot-du-redac-chef-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/maldi-tof-ms-contribution-diagnosis-campylobacter-rectus-multiple-skull-base-and-brain-abscesses 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/maldi-tof-ms-contribution-diagnosis-campylobacter-rectus-multiple-skull-base-and-brain-abscesses 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/maldi-tof-ms-contribution-diagnosis-campylobacter-rectus-multiple-skull-base-and-brain-abscesses 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/accuracy-assessment-surgical-planning-and-three-dimensional-printed-patient-specific-guides 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/accuracy-assessment-surgical-planning-and-three-dimensional-printed-patient-specific-guides 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/accuracy-assessment-surgical-planning-and-three-dimensional-printed-patient-specific-guides 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/dyspnea-and-cardia-cancer-unusual-etiology 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/dyspnea-and-cardia-cancer-unusual-etiology 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/dyspnea-and-cardia-cancer-unusual-etiology 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/post-sir-spheres-surgery-study-p4s-retrospective-analysis-safety-following-hepatic-resection-or 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/post-sir-spheres-surgery-study-p4s-retrospective-analysis-safety-following-hepatic-resection-or 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/post-sir-spheres-surgery-study-p4s-retrospective-analysis-safety-following-hepatic-resection-or 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/les-actualites-en-medecine-factuelle-edition-2017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/les-actualites-en-medecine-factuelle-edition-2017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/les-actualites-en-medecine-factuelle-edition-2017 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/p53-and-mitfbcl-2-identified-key-pathways-acquired-resistance-nras-mutant-melanoma-mek-inhibition 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/p53-and-mitfbcl-2-identified-key-pathways-acquired-resistance-nras-mutant-melanoma-mek-inhibition 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/p53-and-mitfbcl-2-identified-key-pathways-acquired-resistance-nras-mutant-melanoma-mek-inhibition 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/immunotherapy-and-non-small-cell-lung-cancer-revolution 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/immunotherapy-and-non-small-cell-lung-cancer-revolution 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/immunotherapy-and-non-small-cell-lung-cancer-revolution 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/incidence-symptomatic-brain-metastases-extra-pulmonary-small-cell-carcinoma-there-role-prophylactic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/incidence-symptomatic-brain-metastases-extra-pulmonary-small-cell-carcinoma-there-role-prophylactic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/incidence-symptomatic-brain-metastases-extra-pulmonary-small-cell-carcinoma-there-role-prophylactic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/weight-loss-fever-and-arthralgia-43-year-old-man-treated-follicular-lymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/weight-loss-fever-and-arthralgia-43-year-old-man-treated-follicular-lymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/weight-loss-fever-and-arthralgia-43-year-old-man-treated-follicular-lymphoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/unusual-diffuse-liver-18f-fdg-uptake-melanoma-patient-treated-ipilimumab 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/unusual-diffuse-liver-18f-fdg-uptake-melanoma-patient-treated-ipilimumab 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/unusual-diffuse-liver-18f-fdg-uptake-melanoma-patient-treated-ipilimumab 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-ii-study-copanlisib-pi3k-inhibitor-relapsed-or-refractory-indolent-or-aggressive-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/phase-ii-study-copanlisib-pi3k-inhibitor-relapsed-or-refractory-indolent-or-aggressive-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/phase-ii-study-copanlisib-pi3k-inhibitor-relapsed-or-refractory-indolent-or-aggressive-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocytes-breast-cancer-according-tumor-subtype-current-state-art 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocytes-breast-cancer-according-tumor-subtype-current-state-art 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocytes-breast-cancer-according-tumor-subtype-current-state-art 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/viral-induced-hemorrhagic-cystitis-after-allogeneic-hematopoietic-stem-cell-transplant 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/viral-induced-hemorrhagic-cystitis-after-allogeneic-hematopoietic-stem-cell-transplant 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/viral-induced-hemorrhagic-cystitis-after-allogeneic-hematopoietic-stem-cell-transplant 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/unusual-presentation-nasopharyngeal-carcinoma-rectal-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/unusual-presentation-nasopharyngeal-carcinoma-rectal-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/unusual-presentation-nasopharyngeal-carcinoma-rectal-metastasis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cdk4-phosphorylation-status-and-linked-gene-expression-profile-predict-sensitivity-palbociclib 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/cdk4-phosphorylation-status-and-linked-gene-expression-profile-predict-sensitivity-palbociclib 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/cdk4-phosphorylation-status-and-linked-gene-expression-profile-predict-sensitivity-palbociclib 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/comparison-and-immunobiological-characterization-retinoic-acid-inducible-gene-i-receptor-expression 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/comparison-and-immunobiological-characterization-retinoic-acid-inducible-gene-i-receptor-expression 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/comparison-and-immunobiological-characterization-retinoic-acid-inducible-gene-i-receptor-expression 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tackling-immunomonitoring-gastrointestinal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tackling-immunomonitoring-gastrointestinal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tackling-immunomonitoring-gastrointestinal-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/extracellular-vesicles-bone-marrow-stromal-cells-rescue-chronic-lymphocytic-leukemia-b-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/extracellular-vesicles-bone-marrow-stromal-cells-rescue-chronic-lymphocytic-leukemia-b-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/extracellular-vesicles-bone-marrow-stromal-cells-rescue-chronic-lymphocytic-leukemia-b-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/buparlisib-plus-fulvestrant-versus-placebo-plus-fulvestrant-postmenopausal-hormone-receptor-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/buparlisib-plus-fulvestrant-versus-placebo-plus-fulvestrant-postmenopausal-hormone-receptor-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/buparlisib-plus-fulvestrant-versus-placebo-plus-fulvestrant-postmenopausal-hormone-receptor-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-pertuzumab-and-trastuzumab-early-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-pertuzumab-and-trastuzumab-early-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-pertuzumab-and-trastuzumab-early-her2-positive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunoprofiling-adult-derived-human-liver-stemprogenitor-cells-impact-hepatogenic-differentiation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immunoprofiling-adult-derived-human-liver-stemprogenitor-cells-impact-hepatogenic-differentiation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immunoprofiling-adult-derived-human-liver-stemprogenitor-cells-impact-hepatogenic-differentiation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cxcl13-producing-tfh-cells-link-immune-suppression-and-adaptive-memory-human-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/cxcl13-producing-tfh-cells-link-immune-suppression-and-adaptive-memory-human-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/cxcl13-producing-tfh-cells-link-immune-suppression-and-adaptive-memory-human-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/la-17e-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/la-17e-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/la-17e-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/meta-analysis-and-indirect-treatment-comparison-lipegfilgrastim-pegfilgrastim-and-filgrastim 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/meta-analysis-and-indirect-treatment-comparison-lipegfilgrastim-pegfilgrastim-and-filgrastim 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/meta-analysis-and-indirect-treatment-comparison-lipegfilgrastim-pegfilgrastim-and-filgrastim 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/l-ouverture-l-autre-et-la-tolerance-un-pas-oblige-vers-une-societe-plus-sure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/l-ouverture-l-autre-et-la-tolerance-un-pas-oblige-vers-une-societe-plus-sure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/l-ouverture-l-autre-et-la-tolerance-un-pas-oblige-vers-une-societe-plus-sure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/red-blood-cell-transfusion-resuscitation-septic-patients-hematological-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/red-blood-cell-transfusion-resuscitation-septic-patients-hematological-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/red-blood-cell-transfusion-resuscitation-septic-patients-hematological-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/meaningness-colon-cancer-sidedness 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/meaningness-colon-cancer-sidedness 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/meaningness-colon-cancer-sidedness 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/erratum-phylogenetic-analysis-metastatic-progression-breast-cancer-using-somatic-mutations-and-copy 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/erratum-phylogenetic-analysis-metastatic-progression-breast-cancer-using-somatic-mutations-and-copy 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/erratum-phylogenetic-analysis-metastatic-progression-breast-cancer-using-somatic-mutations-and-copy 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocytes-patients-her2-positive-breast-cancer-treated-neoadjuvant 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocytes-patients-her2-positive-breast-cancer-treated-neoadjuvant 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocytes-patients-her2-positive-breast-cancer-treated-neoadjuvant 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/unmet-needs-scientific-approach-older-patients-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/unmet-needs-scientific-approach-older-patients-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/unmet-needs-scientific-approach-older-patients-lymphoma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prolonged-survival-patients-breast-cancer-and-history-brain-metastases-results-preplanned-subgroup 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prolonged-survival-patients-breast-cancer-and-history-brain-metastases-results-preplanned-subgroup 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prolonged-survival-patients-breast-cancer-and-history-brain-metastases-results-preplanned-subgroup 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/translational-genomics-practical-applications-genomic-revolution-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/translational-genomics-practical-applications-genomic-revolution-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/translational-genomics-practical-applications-genomic-revolution-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cis-perturbation-cancer-drivers-htlv-1blv-proviruses-early-determinant-leukemogenesis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cis-perturbation-cancer-drivers-htlv-1blv-proviruses-early-determinant-leukemogenesis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cis-perturbation-cancer-drivers-htlv-1blv-proviruses-early-determinant-leukemogenesis 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/turning-tide-clinical-utility-pd-l1-expression-squamous-cell-carcinoma-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/turning-tide-clinical-utility-pd-l1-expression-squamous-cell-carcinoma-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/turning-tide-clinical-utility-pd-l1-expression-squamous-cell-carcinoma-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/antibiotic-susceptibility-profiles-among-campylobacter-isolates-obtained-international-travelers 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/antibiotic-susceptibility-profiles-among-campylobacter-isolates-obtained-international-travelers 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/antibiotic-susceptibility-profiles-among-campylobacter-isolates-obtained-international-travelers 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/intensive-care-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/intensive-care-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/intensive-care-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reliability-tumor-infiltrating-lymphocyte-and-tertiary-lymphoid-structure-assessment-human-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/reliability-tumor-infiltrating-lymphocyte-and-tertiary-lymphoid-structure-assessment-human-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/reliability-tumor-infiltrating-lymphocyte-and-tertiary-lymphoid-structure-assessment-human-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/editorial-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/editorial-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/editorial-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pregnancy-and-fertility-prefer-study-italian-multicenter-prospective-cohort-study-fertility 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/pregnancy-and-fertility-prefer-study-italian-multicenter-prospective-cohort-study-fertility 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/pregnancy-and-fertility-prefer-study-italian-multicenter-prospective-cohort-study-fertility 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/indocyanine-green-fluorescence-guided-surgery-after-iv-injection-metastatic-colorectal-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/indocyanine-green-fluorescence-guided-surgery-after-iv-injection-metastatic-colorectal-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/indocyanine-green-fluorescence-guided-surgery-after-iv-injection-metastatic-colorectal-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/miliary-metastases-are-associated-epidermal-growth-factor-receptor-mutations-non-small-cell-lung 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/miliary-metastases-are-associated-epidermal-growth-factor-receptor-mutations-non-small-cell-lung 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/miliary-metastases-are-associated-epidermal-growth-factor-receptor-mutations-non-small-cell-lung 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-survival-after-cancer-what-cost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-survival-after-cancer-what-cost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-survival-after-cancer-what-cost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/state-art-oocyte-cryopreservation-female-cancer-patients-critical-review-literature 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/state-art-oocyte-cryopreservation-female-cancer-patients-critical-review-literature 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/state-art-oocyte-cryopreservation-female-cancer-patients-critical-review-literature 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/long-lasting-prophylaxis-iodine-deficiency-after-successful-information-campaign-iodized-salt 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-lasting-prophylaxis-iodine-deficiency-after-successful-information-campaign-iodized-salt 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-lasting-prophylaxis-iodine-deficiency-after-successful-information-campaign-iodized-salt 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/feasibility-tongue-strength-measurements-during-chemoradiotherapy-head-and-neck-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/feasibility-tongue-strength-measurements-during-chemoradiotherapy-head-and-neck-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/feasibility-tongue-strength-measurements-during-chemoradiotherapy-head-and-neck-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/reliability-commercially-available-sleep-and-activity-trackers-manual-switch-sleep-mode-activation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reliability-commercially-available-sleep-and-activity-trackers-manual-switch-sleep-mode-activation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reliability-commercially-available-sleep-and-activity-trackers-manual-switch-sleep-mode-activation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/hashimoto-s-thyroiditis-and-vestibular-dysfunction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hashimoto-s-thyroiditis-and-vestibular-dysfunction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hashimoto-s-thyroiditis-and-vestibular-dysfunction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/need-simplify-informed-consent-documents-cancer-clinical-trials-position-paper-arcad-group 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/need-simplify-informed-consent-documents-cancer-clinical-trials-position-paper-arcad-group 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/need-simplify-informed-consent-documents-cancer-clinical-trials-position-paper-arcad-group 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/characterisation-multifocal-breast-cancer-using-70-gene-signature-clinical-low-risk-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterisation-multifocal-breast-cancer-using-70-gene-signature-clinical-low-risk-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterisation-multifocal-breast-cancer-using-70-gene-signature-clinical-low-risk-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/nontuberculous-mycobacteria-among-pulmonary-tuberculosis-patients-retrospective-belgian-multicenter 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/nontuberculous-mycobacteria-among-pulmonary-tuberculosis-patients-retrospective-belgian-multicenter 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/nontuberculous-mycobacteria-among-pulmonary-tuberculosis-patients-retrospective-belgian-multicenter 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/mesenchymal-stromal-cells-and-toll-receptor-priming-critical-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/mesenchymal-stromal-cells-and-toll-receptor-priming-critical-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/mesenchymal-stromal-cells-and-toll-receptor-priming-critical-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/peritumoral-indocyanine-green-fluorescence-injection-during-transanal-total-mesorectal-excision 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/peritumoral-indocyanine-green-fluorescence-injection-during-transanal-total-mesorectal-excision 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/peritumoral-indocyanine-green-fluorescence-injection-during-transanal-total-mesorectal-excision 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/physical-long-term-side-effects-young-adult-cancer-survivors-germ-cell-tumors-model 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/physical-long-term-side-effects-young-adult-cancer-survivors-germ-cell-tumors-model 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/physical-long-term-side-effects-young-adult-cancer-survivors-germ-cell-tumors-model 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/controversies-about-fertility-and-pregnancy-issues-young-breast-cancer-patients-current-state-art 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/controversies-about-fertility-and-pregnancy-issues-young-breast-cancer-patients-current-state-art 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/controversies-about-fertility-and-pregnancy-issues-young-breast-cancer-patients-current-state-art 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/viable-options-fertility-preservation-breast-cancer-patients-focus-latin-america 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/viable-options-fertility-preservation-breast-cancer-patients-focus-latin-america 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/viable-options-fertility-preservation-breast-cancer-patients-focus-latin-america 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/surgical-treatment-periacetabular-metastatic-lesions 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/surgical-treatment-periacetabular-metastatic-lesions 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/surgical-treatment-periacetabular-metastatic-lesions 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/patterns-care-and-clinical-outcomes-her2-positive-metastatic-breast-cancer-patients-newly-diagnosed 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/patterns-care-and-clinical-outcomes-her2-positive-metastatic-breast-cancer-patients-newly-diagnosed 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/patterns-care-and-clinical-outcomes-her2-positive-metastatic-breast-cancer-patients-newly-diagnosed 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/hard-ball-tennis-player-rare-case-large-calcifying-sertoli-cell-testicular-tumor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hard-ball-tennis-player-rare-case-large-calcifying-sertoli-cell-testicular-tumor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hard-ball-tennis-player-rare-case-large-calcifying-sertoli-cell-testicular-tumor 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/systematic-review-and-meta-analysis-local-resection-or-transanal-endoscopic-microsurgery-versus 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/systematic-review-and-meta-analysis-local-resection-or-transanal-endoscopic-microsurgery-versus 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/systematic-review-and-meta-analysis-local-resection-or-transanal-endoscopic-microsurgery-versus 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/intravenous-iron-therapy-anemic-cancer-patients-review-recently-published-clinical-studies 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/intravenous-iron-therapy-anemic-cancer-patients-review-recently-published-clinical-studies 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/intravenous-iron-therapy-anemic-cancer-patients-review-recently-published-clinical-studies 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prevalence-and-clinical-relevance-tumor-infiltrating-lymphocytes-tils-ductal-carcinoma-situ-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prevalence-and-clinical-relevance-tumor-infiltrating-lymphocytes-tils-ductal-carcinoma-situ-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prevalence-and-clinical-relevance-tumor-infiltrating-lymphocytes-tils-ductal-carcinoma-situ-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/health-related-quality-life-patients-locally-recurrent-or-metastatic-breast-cancer-treated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/health-related-quality-life-patients-locally-recurrent-or-metastatic-breast-cancer-treated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/health-related-quality-life-patients-locally-recurrent-or-metastatic-breast-cancer-treated 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phylogenetic-analysis-metastatic-progression-breast-cancer-using-somatic-mutations-and-copy-number 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/phylogenetic-analysis-metastatic-progression-breast-cancer-using-somatic-mutations-and-copy-number 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/phylogenetic-analysis-metastatic-progression-breast-cancer-using-somatic-mutations-and-copy-number 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/identification-and-evaluation-new-immunoregulatory-genes-mesenchymal-stromal-cells-different 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/identification-and-evaluation-new-immunoregulatory-genes-mesenchymal-stromal-cells-different 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/identification-and-evaluation-new-immunoregulatory-genes-mesenchymal-stromal-cells-different 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/checkpoint-inhibitors-treatment-brain-metastases-non-small-cell-lung-cancer-and-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/checkpoint-inhibitors-treatment-brain-metastases-non-small-cell-lung-cancer-and-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/checkpoint-inhibitors-treatment-brain-metastases-non-small-cell-lung-cancer-and-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vertebral-hemangioma-mimicking-bone-metastasis-68ga-psma-ligand-petct 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vertebral-hemangioma-mimicking-bone-metastasis-68ga-psma-ligand-petct 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vertebral-hemangioma-mimicking-bone-metastasis-68ga-psma-ligand-petct 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-diabetes-insulin-and-metformin-use-outcome-patients-human-epidermal-growth-factor-receptor-2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-diabetes-insulin-and-metformin-use-outcome-patients-human-epidermal-growth-factor-receptor-2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-diabetes-insulin-and-metformin-use-outcome-patients-human-epidermal-growth-factor-receptor-2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/transcriptomic-and-genomic-features-invasive-lobular-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/transcriptomic-and-genomic-features-invasive-lobular-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/transcriptomic-and-genomic-features-invasive-lobular-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/prevention-and-treatment-complications-selective-internal-radiation-therapy-expert-guidance-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prevention-and-treatment-complications-selective-internal-radiation-therapy-expert-guidance-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prevention-and-treatment-complications-selective-internal-radiation-therapy-expert-guidance-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/regional-nodal-irradiation-after-breast-conserving-surgery-early-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/regional-nodal-irradiation-after-breast-conserving-surgery-early-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/regional-nodal-irradiation-after-breast-conserving-surgery-early-her2-positive-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-ii-study-combined-ridaforolimus-and-dalotuzumab-compared-exemestane-patients-estrogen 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-ii-study-combined-ridaforolimus-and-dalotuzumab-compared-exemestane-patients-estrogen 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-ii-study-combined-ridaforolimus-and-dalotuzumab-compared-exemestane-patients-estrogen 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/somatic-mutations-reveal-asymmetric-cellular-dynamics-early-human-embryo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/somatic-mutations-reveal-asymmetric-cellular-dynamics-early-human-embryo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/somatic-mutations-reveal-asymmetric-cellular-dynamics-early-human-embryo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/her2-overexpressing-breast-cancers-amplify-fgfr-signaling-upon-acquisition-resistance-dual 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/her2-overexpressing-breast-cancers-amplify-fgfr-signaling-upon-acquisition-resistance-dual 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/her2-overexpressing-breast-cancers-amplify-fgfr-signaling-upon-acquisition-resistance-dual 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cognitive-compensatory-processes-older-clinically-fit-patients-hematologic-malignancies-undergoing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cognitive-compensatory-processes-older-clinically-fit-patients-hematologic-malignancies-undergoing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cognitive-compensatory-processes-older-clinically-fit-patients-hematologic-malignancies-undergoing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-stromal-foxp3-positive-t-cell-number-combined-tumor-stage-improved-prognosis-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-stromal-foxp3-positive-t-cell-number-combined-tumor-stage-improved-prognosis-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-stromal-foxp3-positive-t-cell-number-combined-tumor-stage-improved-prognosis-head-and-neck 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/apple-trial-feasibility-and-activity-azd9291-osimertinib-treatment-positive-plasma-t790m-egfr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/apple-trial-feasibility-and-activity-azd9291-osimertinib-treatment-positive-plasma-t790m-egfr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/apple-trial-feasibility-and-activity-azd9291-osimertinib-treatment-positive-plasma-t790m-egfr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/predictors-physicians-communication-performance-decision-making-encounter-simulated-advanced-stage 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/predictors-physicians-communication-performance-decision-making-encounter-simulated-advanced-stage 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/predictors-physicians-communication-performance-decision-making-encounter-simulated-advanced-stage 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/skeletal-muscle-stem-cells-innovative-and-minimally-invasive-process-multiple-species 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/skeletal-muscle-stem-cells-innovative-and-minimally-invasive-process-multiple-species 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/skeletal-muscle-stem-cells-innovative-and-minimally-invasive-process-multiple-species 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/androgen-deprivation-therapy-treatment-locally-advanced-nonmetastatic-prostate-cancer-practical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/androgen-deprivation-therapy-treatment-locally-advanced-nonmetastatic-prostate-cancer-practical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/androgen-deprivation-therapy-treatment-locally-advanced-nonmetastatic-prostate-cancer-practical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/value-68ga-dotatate-pet-ct-diagnosis-endometriosis-pilot-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/value-68ga-dotatate-pet-ct-diagnosis-endometriosis-pilot-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/value-68ga-dotatate-pet-ct-diagnosis-endometriosis-pilot-study 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/vitro-fertilization-when-men-women-or-both-partners-are-positive-hiv-case-control-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vitro-fertilization-when-men-women-or-both-partners-are-positive-hiv-case-control-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vitro-fertilization-when-men-women-or-both-partners-are-positive-hiv-case-control-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lenalidomide-bortezomib-and-dexamethasone-transplantation-myeloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/lenalidomide-bortezomib-and-dexamethasone-transplantation-myeloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/lenalidomide-bortezomib-and-dexamethasone-transplantation-myeloma 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/concurrent-versus-sequential-adjuvant-chemo-endocrine-therapy-hormone-receptor-positive-early-stage 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/concurrent-versus-sequential-adjuvant-chemo-endocrine-therapy-hormone-receptor-positive-early-stage 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/concurrent-versus-sequential-adjuvant-chemo-endocrine-therapy-hormone-receptor-positive-early-stage 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/new-agents-endocrine-resistance-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-agents-endocrine-resistance-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-agents-endocrine-resistance-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lymphatic-drainages-paravertebral-and-pararenal-lymph-nodes-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/lymphatic-drainages-paravertebral-and-pararenal-lymph-nodes-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/lymphatic-drainages-paravertebral-and-pararenal-lymph-nodes-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/lymphatic-drainage-paravertebral-lymph-nodes-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/lymphatic-drainage-paravertebral-lymph-nodes-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/lymphatic-drainage-paravertebral-lymph-nodes-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/professional-burnout-european-young-oncologists-results-european-society-medical-oncology-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/professional-burnout-european-young-oncologists-results-european-society-medical-oncology-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/professional-burnout-european-young-oncologists-results-european-society-medical-oncology-esmo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/near-infrared-fluorescence-lymphatic-imaging-reconsider-occlusion-pressure-superficial-lymphatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/near-infrared-fluorescence-lymphatic-imaging-reconsider-occlusion-pressure-superficial-lymphatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/near-infrared-fluorescence-lymphatic-imaging-reconsider-occlusion-pressure-superficial-lymphatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/advances-urothelial-bladder-cancer-immunotherapy-dawn-new-age-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/advances-urothelial-bladder-cancer-immunotherapy-dawn-new-age-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/advances-urothelial-bladder-cancer-immunotherapy-dawn-new-age-treatment 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/retrospective-chart-review-hospitalizations-and-costs-associated-treatment-adults-philadelphia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/retrospective-chart-review-hospitalizations-and-costs-associated-treatment-adults-philadelphia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/retrospective-chart-review-hospitalizations-and-costs-associated-treatment-adults-philadelphia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/pharmacotherapy-protect-ovarian-function-and-fertility-during-cancer-treatment 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/pharmacotherapy-protect-ovarian-function-and-fertility-during-cancer-treatment 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/pharmacotherapy-protect-ovarian-function-and-fertility-during-cancer-treatment 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/implementation-d-un-programme-de-soins-oncologiques-en-consultation-multidisciplinaire 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/implementation-d-un-programme-de-soins-oncologiques-en-consultation-multidisciplinaire 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/implementation-d-un-programme-de-soins-oncologiques-en-consultation-multidisciplinaire 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/faut-il-reevaluer-les-indications-pour-l-utilisation-des-facteurs-stimulant-la-granulopoiese-en 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/faut-il-reevaluer-les-indications-pour-l-utilisation-des-facteurs-stimulant-la-granulopoiese-en 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/faut-il-reevaluer-les-indications-pour-l-utilisation-des-facteurs-stimulant-la-granulopoiese-en 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/seromas-and-punctures-after-complete-axillary-node-dissection-breast-cancer-differences-between 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/seromas-and-punctures-after-complete-axillary-node-dissection-breast-cancer-differences-between 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/seromas-and-punctures-after-complete-axillary-node-dissection-breast-cancer-differences-between 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-2 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature-part-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-anastomosis-leakage-post-ralp-simple-trick-complex-situation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-anastomosis-leakage-post-ralp-simple-trick-complex-situation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-anastomosis-leakage-post-ralp-simple-trick-complex-situation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eortc-module-quality-life-patients-thyroid-cancer-phase-iii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eortc-module-quality-life-patients-thyroid-cancer-phase-iii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eortc-module-quality-life-patients-thyroid-cancer-phase-iii 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/are-life-saving-anticancer-drugs-reaching-all-patients-patterns-and-discrepancies-trastuzumab-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/are-life-saving-anticancer-drugs-reaching-all-patients-patterns-and-discrepancies-trastuzumab-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/are-life-saving-anticancer-drugs-reaching-all-patients-patterns-and-discrepancies-trastuzumab-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/data-ho-1-and-cd200-protein-secretion-during-t-cells-and-mesenchymal-stromal-cells-co-cultures 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/data-ho-1-and-cd200-protein-secretion-during-t-cells-and-mesenchymal-stromal-cells-co-cultures 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/data-ho-1-and-cd200-protein-secretion-during-t-cells-and-mesenchymal-stromal-cells-co-cultures 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/which-factors-predict-overall-survival-patients-metastatic-castration-resistant-prostate-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/which-factors-predict-overall-survival-patients-metastatic-castration-resistant-prostate-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/which-factors-predict-overall-survival-patients-metastatic-castration-resistant-prostate-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/repression-human-t-lymphotropic-virus-type-1-long-terminal-repeat-sense-transcription-sp1 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/repression-human-t-lymphotropic-virus-type-1-long-terminal-repeat-sense-transcription-sp1 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/repression-human-t-lymphotropic-virus-type-1-long-terminal-repeat-sense-transcription-sp1 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/hrdetect-predictor-brca1-and-brca2-deficiency-based-mutational-signatures 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/hrdetect-predictor-brca1-and-brca2-deficiency-based-mutational-signatures 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/hrdetect-predictor-brca1-and-brca2-deficiency-based-mutational-signatures 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/autoimmune-paraneoplastic-syndromes-associated-lung-cancer-systematic-review-literature 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vitro-fertilization-women-infected-hepatitis-c-virus-matched-case-control-study-and-systematic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vitro-fertilization-women-infected-hepatitis-c-virus-matched-case-control-study-and-systematic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vitro-fertilization-women-infected-hepatitis-c-virus-matched-case-control-study-and-systematic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/results-belgian-mantle-cell-lymphoma-registry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/results-belgian-mantle-cell-lymphoma-registry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/results-belgian-mantle-cell-lymphoma-registry 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/improved-cancer-detection-automated-breast-ultrasound-radiologists-using-computer-aided-detection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improved-cancer-detection-automated-breast-ultrasound-radiologists-using-computer-aided-detection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improved-cancer-detection-automated-breast-ultrasound-radiologists-using-computer-aided-detection 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lorsque-le-doute-s-installe-dans-la-prise-de-decision-therapeutique-la-necessite-de-repenser-la 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lorsque-le-doute-s-installe-dans-la-prise-de-decision-therapeutique-la-necessite-de-repenser-la 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lorsque-le-doute-s-installe-dans-la-prise-de-decision-therapeutique-la-necessite-de-repenser-la 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-research-febrile-neutropenia-cancer-patients-past-achievements-and-perspectives-future 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/clinical-research-febrile-neutropenia-cancer-patients-past-achievements-and-perspectives-future 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/clinical-research-febrile-neutropenia-cancer-patients-past-achievements-and-perspectives-future 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/onco-haematology-geriatry-impact-cognitive-disorders 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/onco-haematology-geriatry-impact-cognitive-disorders 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/onco-haematology-geriatry-impact-cognitive-disorders 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/belgium-recommendations-management-acute-promyelocytic-leukaemia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/belgium-recommendations-management-acute-promyelocytic-leukaemia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/belgium-recommendations-management-acute-promyelocytic-leukaemia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/bhs-guidelines-treatment-large-granular-lymphocyte-and-cronic-prolymphocytic-leukaemias 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/bhs-guidelines-treatment-large-granular-lymphocyte-and-cronic-prolymphocytic-leukaemias 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/bhs-guidelines-treatment-large-granular-lymphocyte-and-cronic-prolymphocytic-leukaemias 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/which-factors-predict-overall-survival-metastatic-castration-resistant-prostate-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/which-factors-predict-overall-survival-metastatic-castration-resistant-prostate-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/which-factors-predict-overall-survival-metastatic-castration-resistant-prostate-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/guidance-prevention-and-treatment-venous-thromboembolism-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/guidance-prevention-and-treatment-venous-thromboembolism-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/guidance-prevention-and-treatment-venous-thromboembolism-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/future-access-innovative-medicines-cancer-therapy-towards-conditional-dialogue-fostering-affordable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/future-access-innovative-medicines-cancer-therapy-towards-conditional-dialogue-fostering-affordable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/future-access-innovative-medicines-cancer-therapy-towards-conditional-dialogue-fostering-affordable 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/progressive-multifocal-leukoencephalopathy-mimicking-cerebral-metastases-patient-treated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/progressive-multifocal-leukoencephalopathy-mimicking-cerebral-metastases-patient-treated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/progressive-multifocal-leukoencephalopathy-mimicking-cerebral-metastases-patient-treated 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/do-guidelines-oncology-need-evolve 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/do-guidelines-oncology-need-evolve 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/do-guidelines-oncology-need-evolve 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-endocrine-therapy-preand-perimenopausal-women-breast-cancer-practice-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-endocrine-therapy-preand-perimenopausal-women-breast-cancer-practice-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-endocrine-therapy-preand-perimenopausal-women-breast-cancer-practice-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/dose-seeking-phase-i-trials-currently-approved-molecular-targeted-therapies-usa-dose-limiting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/dose-seeking-phase-i-trials-currently-approved-molecular-targeted-therapies-usa-dose-limiting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/dose-seeking-phase-i-trials-currently-approved-molecular-targeted-therapies-usa-dose-limiting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/eribulin-soft-tissue-sarcoma-therapeutic-landscape-little-good-then-more-better 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/eribulin-soft-tissue-sarcoma-therapeutic-landscape-little-good-then-more-better 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/eribulin-soft-tissue-sarcoma-therapeutic-landscape-little-good-then-more-better 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/moderne-indications-endoscopic-endonasal-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/moderne-indications-endoscopic-endonasal-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/moderne-indications-endoscopic-endonasal-surgery 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/screening-leading-diagnosis-c-cell-disease-tyroid-cancer-clinical-casebook-d-cooper-c-durante-eds 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/screening-leading-diagnosis-c-cell-disease-tyroid-cancer-clinical-casebook-d-cooper-c-durante-eds 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/screening-leading-diagnosis-c-cell-disease-tyroid-cancer-clinical-casebook-d-cooper-c-durante-eds 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immune-infiltrate-prostate-bladder-and-testicular-tumors-old-friend-new-challenges 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-infiltrate-prostate-bladder-and-testicular-tumors-old-friend-new-challenges 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-infiltrate-prostate-bladder-and-testicular-tumors-old-friend-new-challenges 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/tumour-infiltrating-lymphocytes-and-emerging-role-immunotherapy-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumour-infiltrating-lymphocytes-and-emerging-role-immunotherapy-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumour-infiltrating-lymphocytes-and-emerging-role-immunotherapy-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/accuracy-and-precision-assessment-activity-quantification-individualized-dosimetry-177lu-dotatate 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/accuracy-and-precision-assessment-activity-quantification-individualized-dosimetry-177lu-dotatate 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/accuracy-and-precision-assessment-activity-quantification-individualized-dosimetry-177lu-dotatate 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/role-troponins-i-and-t-and-n-terminal-prohormone-brain-natriuretic-peptide-monitoring-cardiac 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/role-troponins-i-and-t-and-n-terminal-prohormone-brain-natriuretic-peptide-monitoring-cardiac 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/role-troponins-i-and-t-and-n-terminal-prohormone-brain-natriuretic-peptide-monitoring-cardiac 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/study-microrna-expression-profile-foreskin-derived-mesenchymal-stromal-cells-following-inflammation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/study-microrna-expression-profile-foreskin-derived-mesenchymal-stromal-cells-following-inflammation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/study-microrna-expression-profile-foreskin-derived-mesenchymal-stromal-cells-following-inflammation 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/old-age-extra-risk-febrile-neutropenia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/old-age-extra-risk-febrile-neutropenia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/old-age-extra-risk-febrile-neutropenia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pathway-level-alterations-rather-mutations-single-genes-predict-response-her2-targeted-therapies-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pathway-level-alterations-rather-mutations-single-genes-predict-response-her2-targeted-therapies-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pathway-level-alterations-rather-mutations-single-genes-predict-response-her2-targeted-therapies-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/ovarian-function-suppression-premenopausal-women-early-stage-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/ovarian-function-suppression-premenopausal-women-early-stage-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/ovarian-function-suppression-premenopausal-women-early-stage-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-oncology-hermes-european-curriculum-recommendations-training-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-oncology-hermes-european-curriculum-recommendations-training-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-oncology-hermes-european-curriculum-recommendations-training-thoracic-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/corrigendum-3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3-breast-31 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/corrigendum-3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3-breast-31 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/corrigendum-3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3-breast-31 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/foreskin-source-immunotherapeutic-mesenchymal-stromal-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/foreskin-source-immunotherapeutic-mesenchymal-stromal-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/foreskin-source-immunotherapeutic-mesenchymal-stromal-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/three-trocars-laparoscopic-total-gastrectomy-d2-lymphadenectomy-intracorporeal-manual 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/three-trocars-laparoscopic-total-gastrectomy-d2-lymphadenectomy-intracorporeal-manual 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/three-trocars-laparoscopic-total-gastrectomy-d2-lymphadenectomy-intracorporeal-manual 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/there-still-role-cytotoxic-chemotherapy-after-targeted-therapy-and-immunotherapy-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/there-still-role-cytotoxic-chemotherapy-after-targeted-therapy-and-immunotherapy-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/there-still-role-cytotoxic-chemotherapy-after-targeted-therapy-and-immunotherapy-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/11-years-follow-trastuzumab-after-adjuvant-chemotherapy-her2-positive-early-breast-cancer-final 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/11-years-follow-trastuzumab-after-adjuvant-chemotherapy-her2-positive-early-breast-cancer-final 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/11-years-follow-trastuzumab-after-adjuvant-chemotherapy-her2-positive-early-breast-cancer-final 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bladder-cancer-immunotherapy-swinging-fences 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bladder-cancer-immunotherapy-swinging-fences 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bladder-cancer-immunotherapy-swinging-fences 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/little-help-steroids-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/little-help-steroids-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/little-help-steroids-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-role-androgen-receptor-patients-early-stage-breast-cancer-meta-analysis-clinical-and 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-role-androgen-receptor-patients-early-stage-breast-cancer-meta-analysis-clinical-and 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-role-androgen-receptor-patients-early-stage-breast-cancer-meta-analysis-clinical-and 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/accuracy-fdg-petct-colorectal-peritoneal-carcinomatosis-potential-tool-evaluation-chemotherapeutic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/accuracy-fdg-petct-colorectal-peritoneal-carcinomatosis-potential-tool-evaluation-chemotherapeutic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/accuracy-fdg-petct-colorectal-peritoneal-carcinomatosis-potential-tool-evaluation-chemotherapeutic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocytes-gastrointestinal-tumors-controversies-and-future-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocytes-gastrointestinal-tumors-controversies-and-future-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocytes-gastrointestinal-tumors-controversies-and-future-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/tumor-infiltrating-lymphocyte-composition-organization-and-pd-1-pd-l1-expression-are-linked-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/tumor-infiltrating-lymphocyte-composition-organization-and-pd-1-pd-l1-expression-are-linked-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/tumor-infiltrating-lymphocyte-composition-organization-and-pd-1-pd-l1-expression-are-linked-breast 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/70-gene-signature-early-stage-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/70-gene-signature-early-stage-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/70-gene-signature-early-stage-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/biopsies-internal-mammary-sentinel-lymph-nodes-breast-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/biopsies-internal-mammary-sentinel-lymph-nodes-breast-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/biopsies-internal-mammary-sentinel-lymph-nodes-breast-cancer 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/foxp1-key-regulator-quiescence-healthy-human-cd3-cd4-t-cells-and-constitutively-repressed-cd3-cd4-t 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/foxp1-key-regulator-quiescence-healthy-human-cd3-cd4-t-cells-and-constitutively-repressed-cd3-cd4-t 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/foxp1-key-regulator-quiescence-healthy-human-cd3-cd4-t-cells-and-constitutively-repressed-cd3-cd4-t 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/quality-life-after-robotic-prostatectomy-impact-bmi-and-age-urinary-incontinence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/quality-life-after-robotic-prostatectomy-impact-bmi-and-age-urinary-incontinence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/quality-life-after-robotic-prostatectomy-impact-bmi-and-age-urinary-incontinence 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/totally-implantable-vascular-access-device-tivad-placement-modified-technique-takes-post-procedure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/totally-implantable-vascular-access-device-tivad-placement-modified-technique-takes-post-procedure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/totally-implantable-vascular-access-device-tivad-placement-modified-technique-takes-post-procedure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-iii-randomized-trial-comparing-inolimomab-vs-usual-care-steroid-resistant-acute-gvhd 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/phase-iii-randomized-trial-comparing-inolimomab-vs-usual-care-steroid-resistant-acute-gvhd 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/phase-iii-randomized-trial-comparing-inolimomab-vs-usual-care-steroid-resistant-acute-gvhd 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/langerhans-cell-number-strong-and-independent-prognostic-factor-head-and-neck-squamous-cell 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/langerhans-cell-number-strong-and-independent-prognostic-factor-head-and-neck-squamous-cell 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/langerhans-cell-number-strong-and-independent-prognostic-factor-head-and-neck-squamous-cell 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-tet-and-idh-gene-expression-chronic-lymphocytic-leukemia-comparison-normal-b-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-tet-and-idh-gene-expression-chronic-lymphocytic-leukemia-comparison-normal-b-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-tet-and-idh-gene-expression-chronic-lymphocytic-leukemia-comparison-normal-b-cells 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-study-gamma-secretase-inhibitor-pf-03084014-combination-docetaxel-patients-advanced-triple 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-study-gamma-secretase-inhibitor-pf-03084014-combination-docetaxel-patients-advanced-triple 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-study-gamma-secretase-inhibitor-pf-03084014-combination-docetaxel-patients-advanced-triple 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/comparing-conventional-laparoscopic-robotic-assisted-extended-pelvic-lymph-node-dissection-men 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comparing-conventional-laparoscopic-robotic-assisted-extended-pelvic-lymph-node-dissection-men 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comparing-conventional-laparoscopic-robotic-assisted-extended-pelvic-lymph-node-dissection-men 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phosphoethanolamine-and-danger-unproven-drugs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phosphoethanolamine-and-danger-unproven-drugs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phosphoethanolamine-and-danger-unproven-drugs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cancer-immunotherapy-lab-clinical-applications-potential-impact-cancer-centres-organisation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-immunotherapy-lab-clinical-applications-potential-impact-cancer-centres-organisation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-immunotherapy-lab-clinical-applications-potential-impact-cancer-centres-organisation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/i-spy-2-optimising-cancer-drug-development-21st-century 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/i-spy-2-optimising-cancer-drug-development-21st-century 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/i-spy-2-optimising-cancer-drug-development-21st-century 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/first-200-consecutive-transumbilical-single-incision-laparoscopic-teps 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/first-200-consecutive-transumbilical-single-incision-laparoscopic-teps 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/first-200-consecutive-transumbilical-single-incision-laparoscopic-teps 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/advances-chemical-pharmacotherapy-manage-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/advances-chemical-pharmacotherapy-manage-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/advances-chemical-pharmacotherapy-manage-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/histological-transformation-alk-rearranged-adenocarcinoma-small-cell-lung-cancer-new-mechanism 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/histological-transformation-alk-rearranged-adenocarcinoma-small-cell-lung-cancer-new-mechanism 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/histological-transformation-alk-rearranged-adenocarcinoma-small-cell-lung-cancer-new-mechanism 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/tumour-infiltrating-lymphocytes-advanced-her2-positive-breast-cancer-treated-pertuzumab-or-placebo 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/tumour-infiltrating-lymphocytes-advanced-her2-positive-breast-cancer-treated-pertuzumab-or-placebo 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/tumour-infiltrating-lymphocytes-advanced-her2-positive-breast-cancer-treated-pertuzumab-or-placebo 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/predictive-factors-associated-biochemical-recurrence-following-radical-prostatectomy-pathological 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/predictive-factors-associated-biochemical-recurrence-following-radical-prostatectomy-pathological 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/predictive-factors-associated-biochemical-recurrence-following-radical-prostatectomy-pathological 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-trastuzumab-10-year-overview-its-benefit 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-trastuzumab-10-year-overview-its-benefit 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-trastuzumab-10-year-overview-its-benefit 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immune-stratification-reveals-subset-pd-1lag-3-double-positive-triple-negative-breast-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-stratification-reveals-subset-pd-1lag-3-double-positive-triple-negative-breast-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-stratification-reveals-subset-pd-1lag-3-double-positive-triple-negative-breast-cancers 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/temporary-ovarian-suppression-during-chemotherapy-preserve-ovarian-function-and-fertility-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/temporary-ovarian-suppression-during-chemotherapy-preserve-ovarian-function-and-fertility-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/temporary-ovarian-suppression-during-chemotherapy-preserve-ovarian-function-and-fertility-breast 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/dose-dense-adjuvant-chemotherapy-premenopausal-breast-cancer-patients-pooled-analysis-mig1-and-gim2 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/dose-dense-adjuvant-chemotherapy-premenopausal-breast-cancer-patients-pooled-analysis-mig1-and-gim2 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/dose-dense-adjuvant-chemotherapy-premenopausal-breast-cancer-patients-pooled-analysis-mig1-and-gim2 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/polyic-and-cpg-synergize-anti-erbb2-mab-treatment-breast-tumors-resistant-immune-checkpoint 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/polyic-and-cpg-synergize-anti-erbb2-mab-treatment-breast-tumors-resistant-immune-checkpoint 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/polyic-and-cpg-synergize-anti-erbb2-mab-treatment-breast-tumors-resistant-immune-checkpoint 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/noninvasive-ventilation-during-acute-respiratory-distress-syndrome-patients-cancer-trends-use-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/noninvasive-ventilation-during-acute-respiratory-distress-syndrome-patients-cancer-trends-use-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/noninvasive-ventilation-during-acute-respiratory-distress-syndrome-patients-cancer-trends-use-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-impact-68-ga-psma-petct-prostate-cancer-patients-rising-psa-after-treatment-curative 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/clinical-impact-68-ga-psma-petct-prostate-cancer-patients-rising-psa-after-treatment-curative 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/clinical-impact-68-ga-psma-petct-prostate-cancer-patients-rising-psa-after-treatment-curative 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-m-lambertini-et-al 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/reply-m-lambertini-et-al 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/reply-m-lambertini-et-al 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immune-checkpoint-inhibitors-renal-side-effects-and-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-checkpoint-inhibitors-renal-side-effects-and-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-checkpoint-inhibitors-renal-side-effects-and-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/dermatologic-adverse-events-checkpoint-inhibitors-what-oncologist-should-know 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/dermatologic-adverse-events-checkpoint-inhibitors-what-oncologist-should-know 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/dermatologic-adverse-events-checkpoint-inhibitors-what-oncologist-should-know 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/metadcn-meta-analysis-framework-differential-co-expression-network-detection-application-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/metadcn-meta-analysis-framework-differential-co-expression-network-detection-application-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/metadcn-meta-analysis-framework-differential-co-expression-network-detection-application-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/apport-des-biopsies-ciblees-par-fusion-d-image-usirmmp-en-complement-des-biopsies-systematisees 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/apport-des-biopsies-ciblees-par-fusion-d-image-usirmmp-en-complement-des-biopsies-systematisees 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/apport-des-biopsies-ciblees-par-fusion-d-image-usirmmp-en-complement-des-biopsies-systematisees 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/3rd-eso-esmo-international-consensus-guidelines-advanced-breast-cancer-abc-3-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/regard-perrier-et-al 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/regard-perrier-et-al 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/regard-perrier-et-al 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/protein-phosphatase-2a-regulatory-subunit-pr70-gonosomal-melanoma-tumor-suppressor-gene 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/protein-phosphatase-2a-regulatory-subunit-pr70-gonosomal-melanoma-tumor-suppressor-gene 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/protein-phosphatase-2a-regulatory-subunit-pr70-gonosomal-melanoma-tumor-suppressor-gene 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improvement-sleep-architecture-parameters-cirrhotic-patients-recurrent-hepatic-encephalopathy-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improvement-sleep-architecture-parameters-cirrhotic-patients-recurrent-hepatic-encephalopathy-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improvement-sleep-architecture-parameters-cirrhotic-patients-recurrent-hepatic-encephalopathy-use 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/randomized-phase-iii-trial-erlotinib-versus-docetaxel-patients-advanced-squamous-cell-non-small 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/randomized-phase-iii-trial-erlotinib-versus-docetaxel-patients-advanced-squamous-cell-non-small 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/randomized-phase-iii-trial-erlotinib-versus-docetaxel-patients-advanced-squamous-cell-non-small 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fatal-community-acquired-ribotype-002-clostridium-difficile-bacteremia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/fatal-community-acquired-ribotype-002-clostridium-difficile-bacteremia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/fatal-community-acquired-ribotype-002-clostridium-difficile-bacteremia 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/contribution-rapid-influenza-diagnostic-test-manage-hospitalized-patients-suspected-influenza 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/contribution-rapid-influenza-diagnostic-test-manage-hospitalized-patients-suspected-influenza 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/contribution-rapid-influenza-diagnostic-test-manage-hospitalized-patients-suspected-influenza 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/human-hepatic-stellate-cells-and-inflammation-regulated-cytokine-network-balance 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/human-hepatic-stellate-cells-and-inflammation-regulated-cytokine-network-balance 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/human-hepatic-stellate-cells-and-inflammation-regulated-cytokine-network-balance 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/concurrent-driver-mutationsrearrangements-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/concurrent-driver-mutationsrearrangements-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/concurrent-driver-mutationsrearrangements-non-small-cell-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cabozantinib-metastatic-breast-carcinoma-results-phase-ii-placebo-controlled-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cabozantinib-metastatic-breast-carcinoma-results-phase-ii-placebo-controlled-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cabozantinib-metastatic-breast-carcinoma-results-phase-ii-placebo-controlled-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/threat-posed-unproven-drugs-medical-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/threat-posed-unproven-drugs-medical-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/threat-posed-unproven-drugs-medical-oncology 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-cells-and-bone-marrow-mesenchymal-stromal-cells-regulated-modulation-breast-tumor 2024-03-24T07:00:04+01:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-cells-and-bone-marrow-mesenchymal-stromal-cells-regulated-modulation-breast-tumor 2024-03-24T07:00:04+01:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-cells-and-bone-marrow-mesenchymal-stromal-cells-regulated-modulation-breast-tumor 2024-03-24T07:00:04+01:00 0.5 https://bordet.makemeweb.dev/en/comparing-hifu-hemiablation-robotic-radical-prostatectomy-management-unilateral-prostate-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comparing-hifu-hemiablation-robotic-radical-prostatectomy-management-unilateral-prostate-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comparing-hifu-hemiablation-robotic-radical-prostatectomy-management-unilateral-prostate-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/twenty-years-anti-her2-therapy-associated-cardiotoxicity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/twenty-years-anti-her2-therapy-associated-cardiotoxicity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/twenty-years-anti-her2-therapy-associated-cardiotoxicity 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/comments-intraoperative-near-infrared-fluorescence-imaging-using-indocyanine-green-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/comments-intraoperative-near-infrared-fluorescence-imaging-using-indocyanine-green-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/comments-intraoperative-near-infrared-fluorescence-imaging-using-indocyanine-green-colorectal 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/esmo-asco-recommendations-global-curriculum-medical-oncology-edition-2016 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/esmo-asco-recommendations-global-curriculum-medical-oncology-edition-2016 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/esmo-asco-recommendations-global-curriculum-medical-oncology-edition-2016 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/analysing-data-patient-reported-outcome-and-quality-life-endpoints-cancer-clinical-trials-start 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/analysing-data-patient-reported-outcome-and-quality-life-endpoints-cancer-clinical-trials-start 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/analysing-data-patient-reported-outcome-and-quality-life-endpoints-cancer-clinical-trials-start 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improving-anxiety-regulation-patients-breast-cancer-beginning-survivorship-period-randomized 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improving-anxiety-regulation-patients-breast-cancer-beginning-survivorship-period-randomized 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improving-anxiety-regulation-patients-breast-cancer-beginning-survivorship-period-randomized 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/are-intensive-cares-worthwhile-breast-cancer-patients-experience-oncological-icu 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/are-intensive-cares-worthwhile-breast-cancer-patients-experience-oncological-icu 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/are-intensive-cares-worthwhile-breast-cancer-patients-experience-oncological-icu 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/low-dose-clofarabine-combination-standard-remission-induction-patients-18-60-years-previously 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/low-dose-clofarabine-combination-standard-remission-induction-patients-18-60-years-previously 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/low-dose-clofarabine-combination-standard-remission-induction-patients-18-60-years-previously 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prognostic-performance-adjuvant-online-and-nottingham-prognostic-index-young-breast-cancer-patients 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-performance-adjuvant-online-and-nottingham-prognostic-index-young-breast-cancer-patients 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-performance-adjuvant-online-and-nottingham-prognostic-index-young-breast-cancer-patients 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/serum-free-light-chains-should-be-target-response-evaluation-light-chain-multiple-myeloma-rather 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/serum-free-light-chains-should-be-target-response-evaluation-light-chain-multiple-myeloma-rather 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/serum-free-light-chains-should-be-target-response-evaluation-light-chain-multiple-myeloma-rather 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/targeted-deep-sequencing-reveals-clinically-relevant-subclonal-ighv-rearrangements-chronic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-deep-sequencing-reveals-clinically-relevant-subclonal-ighv-rearrangements-chronic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-deep-sequencing-reveals-clinically-relevant-subclonal-ighv-rearrangements-chronic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mediastinal-grey-zone-lymphoma-clinico-pathological-characteristics-and-outcomes-99-patients-lysa 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/mediastinal-grey-zone-lymphoma-clinico-pathological-characteristics-and-outcomes-99-patients-lysa 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/mediastinal-grey-zone-lymphoma-clinico-pathological-characteristics-and-outcomes-99-patients-lysa 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/targeted-adjuvant-therapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-adjuvant-therapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-adjuvant-therapy-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/soft-tissue-sarcoma-extremities-pending-questions-surgery-and-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/soft-tissue-sarcoma-extremities-pending-questions-surgery-and-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/soft-tissue-sarcoma-extremities-pending-questions-surgery-and-radiotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/comparing-conventional-laparoscopic-robotic-assisted-extended-pelvic-lymph-node-dissection-men-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comparing-conventional-laparoscopic-robotic-assisted-extended-pelvic-lymph-node-dissection-men-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comparing-conventional-laparoscopic-robotic-assisted-extended-pelvic-lymph-node-dissection-men-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fluorescence-imaging-after-indocyanine-green-injection-detection-peritoneal-metastases-patients 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/fluorescence-imaging-after-indocyanine-green-injection-detection-peritoneal-metastases-patients 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/fluorescence-imaging-after-indocyanine-green-injection-detection-peritoneal-metastases-patients 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/salvage-esophagectomy-after-failure-definitive-radiochemotherapy-esophageal-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/salvage-esophagectomy-after-failure-definitive-radiochemotherapy-esophageal-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/salvage-esophagectomy-after-failure-definitive-radiochemotherapy-esophageal-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/relevance-tumor-infiltrating-immune-cell-composition-and-functionality-disease-outcome-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/relevance-tumor-infiltrating-immune-cell-composition-and-functionality-disease-outcome-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/relevance-tumor-infiltrating-immune-cell-composition-and-functionality-disease-outcome-breast 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/increased-mortality-hematological-malignancy-patients-acute-respiratory-failure-undetermined 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/increased-mortality-hematological-malignancy-patients-acute-respiratory-failure-undetermined 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/increased-mortality-hematological-malignancy-patients-acute-respiratory-failure-undetermined 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-flow-nasal-cannula-oxygenation-immunocompromised-patients-acute-hypoxemic-respiratory-failure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-flow-nasal-cannula-oxygenation-immunocompromised-patients-acute-hypoxemic-respiratory-failure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-flow-nasal-cannula-oxygenation-immunocompromised-patients-acute-hypoxemic-respiratory-failure 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/levator-ani-necrosis-exceptional-complication-occurring-after-high-intensity-focused-ultrasound 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/levator-ani-necrosis-exceptional-complication-occurring-after-high-intensity-focused-ultrasound 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/levator-ani-necrosis-exceptional-complication-occurring-after-high-intensity-focused-ultrasound 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rna-sequencing-predict-response-neoadjuvant-anti-her2-therapy-secondary-analysis-neoaltto 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/rna-sequencing-predict-response-neoadjuvant-anti-her2-therapy-secondary-analysis-neoaltto 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/rna-sequencing-predict-response-neoadjuvant-anti-her2-therapy-secondary-analysis-neoaltto 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-genome-and-transcriptome-integration-implicates-specific-mutational-signatures-immune 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-genome-and-transcriptome-integration-implicates-specific-mutational-signatures-immune 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-genome-and-transcriptome-integration-implicates-specific-mutational-signatures-immune 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/somatic-mutation-copy-number-and-transcriptomic-profiles-primary-and-matched-metastatic-estrogen 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/somatic-mutation-copy-number-and-transcriptomic-profiles-primary-and-matched-metastatic-estrogen 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/somatic-mutation-copy-number-and-transcriptomic-profiles-primary-and-matched-metastatic-estrogen 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/imaging-colorectal-cancer-progress-and-challenges-clinicians 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/imaging-colorectal-cancer-progress-and-challenges-clinicians 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/imaging-colorectal-cancer-progress-and-challenges-clinicians 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/management-febrile-neutropaenia-esmo-clinical-practice-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-febrile-neutropaenia-esmo-clinical-practice-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-febrile-neutropaenia-esmo-clinical-practice-guidelines 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/sentinel-lymph-node-detection-blue-dye-versus-indocyanine-green-fluorescence-imaging-colon-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/sentinel-lymph-node-detection-blue-dye-versus-indocyanine-green-fluorescence-imaging-colon-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/sentinel-lymph-node-detection-blue-dye-versus-indocyanine-green-fluorescence-imaging-colon-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/management-neutropenic-patients-intensive-care-unit-newborns-excluded-recommendations-expert-panel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/management-neutropenic-patients-intensive-care-unit-newborns-excluded-recommendations-expert-panel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/management-neutropenic-patients-intensive-care-unit-newborns-excluded-recommendations-expert-panel 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-dose-escalation-study-plitidepsin-combination-bevacizumab-patients-refractory-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-dose-escalation-study-plitidepsin-combination-bevacizumab-patients-refractory-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-dose-escalation-study-plitidepsin-combination-bevacizumab-patients-refractory-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bladder-and-vaginal-transitional-cell-carcinoma-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/bladder-and-vaginal-transitional-cell-carcinoma-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/bladder-and-vaginal-transitional-cell-carcinoma-case-report 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/utilization-multiparametric-prostate-magnetic-resonance-imaging-clinical-practice-and-focal-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/utilization-multiparametric-prostate-magnetic-resonance-imaging-clinical-practice-and-focal-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/utilization-multiparametric-prostate-magnetic-resonance-imaging-clinical-practice-and-focal-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/what-role-informed-decision-making 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/what-role-informed-decision-making 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/what-role-informed-decision-making 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/multidisciplinary-questions-thoracic-oncology-team-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multidisciplinary-questions-thoracic-oncology-team-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multidisciplinary-questions-thoracic-oncology-team-experience 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thoracic-oncology-specialist-curriculum-recommendations-thoracic-oncology-training 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thoracic-oncology-specialist-curriculum-recommendations-thoracic-oncology-training 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thoracic-oncology-specialist-curriculum-recommendations-thoracic-oncology-training 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/biomarkers-adverse-events-associated-immune-checkpoint-inhibitors 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/biomarkers-adverse-events-associated-immune-checkpoint-inhibitors 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/biomarkers-adverse-events-associated-immune-checkpoint-inhibitors 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/gli-inhibitor-gant61-kills-melanoma-cells-and-acts-synergy-obatoclax 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/gli-inhibitor-gant61-kills-melanoma-cells-and-acts-synergy-obatoclax 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/gli-inhibitor-gant61-kills-melanoma-cells-and-acts-synergy-obatoclax 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/testicular-germ-cell-tumor-short-and-long-term-side-effects-treatment-among-survivors 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/testicular-germ-cell-tumor-short-and-long-term-side-effects-treatment-among-survivors 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/testicular-germ-cell-tumor-short-and-long-term-side-effects-treatment-among-survivors 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-value-calr-vs-jak2v617f-mutations-splenomegaly-leukemic-transformation-thrombosis-and 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-value-calr-vs-jak2v617f-mutations-splenomegaly-leukemic-transformation-thrombosis-and 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-value-calr-vs-jak2v617f-mutations-splenomegaly-leukemic-transformation-thrombosis-and 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/portraying-breast-cancers-long-noncoding-rnas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/portraying-breast-cancers-long-noncoding-rnas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/portraying-breast-cancers-long-noncoding-rnas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pathway-level-alterations-rather-mutations-single-genes-predict-response-her2-targeted-therapies-1 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pathway-level-alterations-rather-mutations-single-genes-predict-response-her2-targeted-therapies-1 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pathway-level-alterations-rather-mutations-single-genes-predict-response-her2-targeted-therapies-1 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cohort-selection-and-management-application-leveraging-standards-based-semantic-interoperability 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/cohort-selection-and-management-application-leveraging-standards-based-semantic-interoperability 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/cohort-selection-and-management-application-leveraging-standards-based-semantic-interoperability 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/endocrine-treatment-breast-cancer-cure-resistance-and-beyond 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/endocrine-treatment-breast-cancer-cure-resistance-and-beyond 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/endocrine-treatment-breast-cancer-cure-resistance-and-beyond 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reply-letter-editor-utilisation-esmo-mcbs-practice-hta-wild-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-letter-editor-utilisation-esmo-mcbs-practice-hta-wild-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-letter-editor-utilisation-esmo-mcbs-practice-hta-wild-et-al 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/will-gemcitabine-monotherapy-be-dethroned-adjuvant-chemotherapy-pancreatic-adenocarcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/will-gemcitabine-monotherapy-be-dethroned-adjuvant-chemotherapy-pancreatic-adenocarcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/will-gemcitabine-monotherapy-be-dethroned-adjuvant-chemotherapy-pancreatic-adenocarcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multifocality-sporadic-medullary-thyroid-carcinoma-international-multicenter-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multifocality-sporadic-medullary-thyroid-carcinoma-international-multicenter-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multifocality-sporadic-medullary-thyroid-carcinoma-international-multicenter-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/38-years-old-female-inflammatory-myofibroblastic-tumor-and-lactic-acidosis 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/38-years-old-female-inflammatory-myofibroblastic-tumor-and-lactic-acidosis 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/38-years-old-female-inflammatory-myofibroblastic-tumor-and-lactic-acidosis 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/feasibility-study-endotag-1-tumor-endothelial-targeting-agent-combination-paclitaxel-followed-fec 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/feasibility-study-endotag-1-tumor-endothelial-targeting-agent-combination-paclitaxel-followed-fec 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/feasibility-study-endotag-1-tumor-endothelial-targeting-agent-combination-paclitaxel-followed-fec 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/circulating-cd3-cd19cd20-igd-cd27highcd38high-plasmablasts-promising-cellular-biomarker-immune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/circulating-cd3-cd19cd20-igd-cd27highcd38high-plasmablasts-promising-cellular-biomarker-immune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/circulating-cd3-cd19cd20-igd-cd27highcd38high-plasmablasts-promising-cellular-biomarker-immune 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/performance-chromid-salmonella-elite-chromogenic-agar-comparison-chromagartm-salmonella-oxoidtm 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/performance-chromid-salmonella-elite-chromogenic-agar-comparison-chromagartm-salmonella-oxoidtm 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/performance-chromid-salmonella-elite-chromogenic-agar-comparison-chromagartm-salmonella-oxoidtm 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/new-generation-breast-cancer-clinical-trials-implementing-molecular-profiling 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-generation-breast-cancer-clinical-trials-implementing-molecular-profiling 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-generation-breast-cancer-clinical-trials-implementing-molecular-profiling 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-landscape-breast-cancer-and-its-interaction-host-immunity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-landscape-breast-cancer-and-its-interaction-host-immunity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-landscape-breast-cancer-and-its-interaction-host-immunity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/adding-checkpoint-inhibitors-tyrosine-kinase-inhibitors-targeting-egfralk-non-small-cell-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adding-checkpoint-inhibitors-tyrosine-kinase-inhibitors-targeting-egfralk-non-small-cell-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adding-checkpoint-inhibitors-tyrosine-kinase-inhibitors-targeting-egfralk-non-small-cell-lung 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vulnerabilities-older-patients-when-cancer-treatment-initiated-does-cognitive-impairment-impact-two 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vulnerabilities-older-patients-when-cancer-treatment-initiated-does-cognitive-impairment-impact-two 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vulnerabilities-older-patients-when-cancer-treatment-initiated-does-cognitive-impairment-impact-two 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/data-nitric-oxide-production-human-bone-marrow-derived-mesenchymal-stromal-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/data-nitric-oxide-production-human-bone-marrow-derived-mesenchymal-stromal-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/data-nitric-oxide-production-human-bone-marrow-derived-mesenchymal-stromal-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/risk-adapted-transplant-strategies-high-risk-hodgkin-lymphoma-are-we-there 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/risk-adapted-transplant-strategies-high-risk-hodgkin-lymphoma-are-we-there 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/risk-adapted-transplant-strategies-high-risk-hodgkin-lymphoma-are-we-there 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-perceptions-and-cosmetic-satisfaction-breast-cancer-patients-undergoing-totally 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-perceptions-and-cosmetic-satisfaction-breast-cancer-patients-undergoing-totally 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-perceptions-and-cosmetic-satisfaction-breast-cancer-patients-undergoing-totally 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/are-virus-induced-cancers-more-sensitive-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/are-virus-induced-cancers-more-sensitive-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/are-virus-induced-cancers-more-sensitive-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/continuous-renal-replacement-therapy-acute-renal-failure-patients-cancer-well-tolerated-adjunct 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/continuous-renal-replacement-therapy-acute-renal-failure-patients-cancer-well-tolerated-adjunct 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/continuous-renal-replacement-therapy-acute-renal-failure-patients-cancer-well-tolerated-adjunct 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/reproductive-behaviors-and-risk-developing-breast-cancer-according-tumor-subtype-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reproductive-behaviors-and-risk-developing-breast-cancer-according-tumor-subtype-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reproductive-behaviors-and-risk-developing-breast-cancer-according-tumor-subtype-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/innovative-approach-older-patients-malignant-hemopathies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/innovative-approach-older-patients-malignant-hemopathies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/innovative-approach-older-patients-malignant-hemopathies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/70-gene-signature-aid-treatment-decisions-early-stage-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/70-gene-signature-aid-treatment-decisions-early-stage-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/70-gene-signature-aid-treatment-decisions-early-stage-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/costs-haematological-disease-high-and-rising 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/costs-haematological-disease-high-and-rising 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/costs-haematological-disease-high-and-rising 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/leiomyomatosis-peritonealis-disseminata-case-report-and-review-literature 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/leiomyomatosis-peritonealis-disseminata-case-report-and-review-literature 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/leiomyomatosis-peritonealis-disseminata-case-report-and-review-literature 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/immune-checkpoint-inhibitors-side-effects-and-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/immune-checkpoint-inhibitors-side-effects-and-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/immune-checkpoint-inhibitors-side-effects-and-management 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improved-survival-patients-calr1-compared-calr2-mutated-primary-myelofibrosis-meta-analysis 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improved-survival-patients-calr1-compared-calr2-mutated-primary-myelofibrosis-meta-analysis 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improved-survival-patients-calr1-compared-calr2-mutated-primary-myelofibrosis-meta-analysis 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/safety-and-tolerability-etirinotecan-pegol-advanced-breast-cancer-analysis-randomized-phase-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/safety-and-tolerability-etirinotecan-pegol-advanced-breast-cancer-analysis-randomized-phase-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/safety-and-tolerability-etirinotecan-pegol-advanced-breast-cancer-analysis-randomized-phase-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/diagnosis-congenital-von-willebrand-disease-during-preoperative-assessment-multiple-myeloma-patient 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/diagnosis-congenital-von-willebrand-disease-during-preoperative-assessment-multiple-myeloma-patient 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/diagnosis-congenital-von-willebrand-disease-during-preoperative-assessment-multiple-myeloma-patient 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/potential-mesenchymal-stromal-cells-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/potential-mesenchymal-stromal-cells-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/potential-mesenchymal-stromal-cells-immunotherapy 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/subgroup-analyses-phase-3-open-label-randomized-study-eribulin-mesylate-versus-capecitabine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/subgroup-analyses-phase-3-open-label-randomized-study-eribulin-mesylate-versus-capecitabine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/subgroup-analyses-phase-3-open-label-randomized-study-eribulin-mesylate-versus-capecitabine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/current-day-precision-oncology-cancer-prevention-screening-drug-development-and-treatment-have-we 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/current-day-precision-oncology-cancer-prevention-screening-drug-development-and-treatment-have-we 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/current-day-precision-oncology-cancer-prevention-screening-drug-development-and-treatment-have-we 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/standardized-evaluation-tumor-infiltrating-lymphocytes-breast-cancer-results-ring-studies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/standardized-evaluation-tumor-infiltrating-lymphocytes-breast-cancer-results-ring-studies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/standardized-evaluation-tumor-infiltrating-lymphocytes-breast-cancer-results-ring-studies 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/single-knot-running-vesicourethral-anastomosis-after-minimally-invasive-prostatectomy-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/single-knot-running-vesicourethral-anastomosis-after-minimally-invasive-prostatectomy-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/single-knot-running-vesicourethral-anastomosis-after-minimally-invasive-prostatectomy-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/metastatic-breast-cancer-odyssey-personalization 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/metastatic-breast-cancer-odyssey-personalization 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/metastatic-breast-cancer-odyssey-personalization 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/health-related-quality-life-locally-advanced-and-metastatic-breast-cancer-methodological-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/health-related-quality-life-locally-advanced-and-metastatic-breast-cancer-methodological-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/health-related-quality-life-locally-advanced-and-metastatic-breast-cancer-methodological-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/do-refined-consensus-guidelines-improve-uniformity-clinical-target-volume-delineation-rectal-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/do-refined-consensus-guidelines-improve-uniformity-clinical-target-volume-delineation-rectal-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/do-refined-consensus-guidelines-improve-uniformity-clinical-target-volume-delineation-rectal-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/ncri-phase-ii-study-chop-combination-ofatumumab-induction-and-maintenance-newly-diagnosed-richter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ncri-phase-ii-study-chop-combination-ofatumumab-induction-and-maintenance-newly-diagnosed-richter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ncri-phase-ii-study-chop-combination-ofatumumab-induction-and-maintenance-newly-diagnosed-richter 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/classical-risk-factors-not-hpv-status-predict-survival-after-chemoradiotherapy-advanced-head-and 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/classical-risk-factors-not-hpv-status-predict-survival-after-chemoradiotherapy-advanced-head-and 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/classical-risk-factors-not-hpv-status-predict-survival-after-chemoradiotherapy-advanced-head-and 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/treatment-anal-dysplasia-hiv-positive-men-who-have-sex-men-large-aids-reference-centre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/treatment-anal-dysplasia-hiv-positive-men-who-have-sex-men-large-aids-reference-centre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/treatment-anal-dysplasia-hiv-positive-men-who-have-sex-men-large-aids-reference-centre 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/news-medical-treatment-young-women-early-stage-her2-negative-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/news-medical-treatment-young-women-early-stage-her2-negative-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/news-medical-treatment-young-women-early-stage-her2-negative-breast-cancer 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/epstein-barr-virus-infection-mammary-epithelial-cells-promotes-malignant-transformation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/epstein-barr-virus-infection-mammary-epithelial-cells-promotes-malignant-transformation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/epstein-barr-virus-infection-mammary-epithelial-cells-promotes-malignant-transformation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/managing-pregnancy-associated-breast-cancer-more-really-better 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/managing-pregnancy-associated-breast-cancer-more-really-better 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/managing-pregnancy-associated-breast-cancer-more-really-better 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/liquid-biopsy-based-clinical-research-early-breast-cancer-eortc-90091-10093-treat-ctc-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/liquid-biopsy-based-clinical-research-early-breast-cancer-eortc-90091-10093-treat-ctc-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/liquid-biopsy-based-clinical-research-early-breast-cancer-eortc-90091-10093-treat-ctc-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/corrigendum-frequent-somatic-transfer-mitochondrial-dna-nuclear-genome-human-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/corrigendum-frequent-somatic-transfer-mitochondrial-dna-nuclear-genome-human-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/corrigendum-frequent-somatic-transfer-mitochondrial-dna-nuclear-genome-human-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/drugs-prescribed-patients-hospitalized-geriatric-oncology-unit-potentially-inappropriate 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/drugs-prescribed-patients-hospitalized-geriatric-oncology-unit-potentially-inappropriate 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/drugs-prescribed-patients-hospitalized-geriatric-oncology-unit-potentially-inappropriate 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/efficacy-weekly-paclitaxel-treatment-single-agent-chemotherapy-following-first-line-cisplatin 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-weekly-paclitaxel-treatment-single-agent-chemotherapy-following-first-line-cisplatin 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-weekly-paclitaxel-treatment-single-agent-chemotherapy-following-first-line-cisplatin 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/severe-prolonged-cough-presenting-manifestation-fip1l1-pdgfra-chronic-eosinophilic-leukaemia-widely 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/severe-prolonged-cough-presenting-manifestation-fip1l1-pdgfra-chronic-eosinophilic-leukaemia-widely 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/severe-prolonged-cough-presenting-manifestation-fip1l1-pdgfra-chronic-eosinophilic-leukaemia-widely 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/loss-arid1a-activates-anxa1-which-serves-predictive-biomarker-trastuzumab-resistance 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/loss-arid1a-activates-anxa1-which-serves-predictive-biomarker-trastuzumab-resistance 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/loss-arid1a-activates-anxa1-which-serves-predictive-biomarker-trastuzumab-resistance 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pharmacodynamics-pharmacokinetics-and-clinical-efficacy-neratinib-her2-positive-breast-cancer-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pharmacodynamics-pharmacokinetics-and-clinical-efficacy-neratinib-her2-positive-breast-cancer-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pharmacodynamics-pharmacokinetics-and-clinical-efficacy-neratinib-her2-positive-breast-cancer-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/checkpoint-inhibitors-outstanding-efficacy-what-cost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/checkpoint-inhibitors-outstanding-efficacy-what-cost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/checkpoint-inhibitors-outstanding-efficacy-what-cost 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/no-evidence-benefit-gonadotropin-releasing-hormone-agonist-preserving-ovarian-function-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/no-evidence-benefit-gonadotropin-releasing-hormone-agonist-preserving-ovarian-function-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/no-evidence-benefit-gonadotropin-releasing-hormone-agonist-preserving-ovarian-function-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/will-testicular-germ-cell-tumors-remain-untargetable 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/will-testicular-germ-cell-tumors-remain-untargetable 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/will-testicular-germ-cell-tumors-remain-untargetable 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/minimally-invasive-colorectal-cancer-surgery-europe-implementation-and-outcomes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/minimally-invasive-colorectal-cancer-surgery-europe-implementation-and-outcomes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/minimally-invasive-colorectal-cancer-surgery-europe-implementation-and-outcomes 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/phase-2-study-trabectedin-patients-hormone-receptor-positive-her-2-negative-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-2-study-trabectedin-patients-hormone-receptor-positive-her-2-negative-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-2-study-trabectedin-patients-hormone-receptor-positive-her-2-negative-advanced-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-novel-bovine-leukemia-virus-blv-antisense-transcripts-deep-sequencing-reveals 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/characterization-novel-bovine-leukemia-virus-blv-antisense-transcripts-deep-sequencing-reveals 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/characterization-novel-bovine-leukemia-virus-blv-antisense-transcripts-deep-sequencing-reveals 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pik3ca-mutations-are-associated-reduced-pathological-complete-response-rates-primary-her2-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/pik3ca-mutations-are-associated-reduced-pathological-complete-response-rates-primary-her2-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/pik3ca-mutations-are-associated-reduced-pathological-complete-response-rates-primary-her2-0 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/pancreatic-small-cell-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pancreatic-small-cell-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pancreatic-small-cell-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/risk-stratification-neck-lesions-detected-sonographically-during-follow-differentiated-thyroid 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/risk-stratification-neck-lesions-detected-sonographically-during-follow-differentiated-thyroid 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/risk-stratification-neck-lesions-detected-sonographically-during-follow-differentiated-thyroid 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/consensus-precision-medicine-metastatic-cancers-report-map-conference 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/consensus-precision-medicine-metastatic-cancers-report-map-conference 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/consensus-precision-medicine-metastatic-cancers-report-map-conference 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/ex-vivo-detection-tumoral-lymph-nodes-colorectal-origin-fluorescence-imaging-after-intraoperative 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ex-vivo-detection-tumoral-lymph-nodes-colorectal-origin-fluorescence-imaging-after-intraoperative 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ex-vivo-detection-tumoral-lymph-nodes-colorectal-origin-fluorescence-imaging-after-intraoperative 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/rare-side-effects-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/rare-side-effects-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/rare-side-effects-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/validation-eortc-qlq-info-25-questionnaire-lebanese-cancer-patients-ignorance-bliss 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/validation-eortc-qlq-info-25-questionnaire-lebanese-cancer-patients-ignorance-bliss 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/validation-eortc-qlq-info-25-questionnaire-lebanese-cancer-patients-ignorance-bliss 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pictilisib-oestrogen-receptor-positive-aromatase-inhibitor-resistant-advanced-or-metastatic-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pictilisib-oestrogen-receptor-positive-aromatase-inhibitor-resistant-advanced-or-metastatic-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pictilisib-oestrogen-receptor-positive-aromatase-inhibitor-resistant-advanced-or-metastatic-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/challenges-treating-premenopausal-women-endocrine-sensitive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/challenges-treating-premenopausal-women-endocrine-sensitive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/challenges-treating-premenopausal-women-endocrine-sensitive-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/performances-h-score-diagnosis-hemophagocytic-lymphohistiocytosis-adult-and-pediatric-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/performances-h-score-diagnosis-hemophagocytic-lymphohistiocytosis-adult-and-pediatric-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/performances-h-score-diagnosis-hemophagocytic-lymphohistiocytosis-adult-and-pediatric-patients 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/lapatinib-related-rash-and-breast-cancer-outcome-altto-phase-iii-randomized-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/lapatinib-related-rash-and-breast-cancer-outcome-altto-phase-iii-randomized-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/lapatinib-related-rash-and-breast-cancer-outcome-altto-phase-iii-randomized-trial 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/side-effects-checkpoint-inhibitor-based-combination-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/side-effects-checkpoint-inhibitor-based-combination-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/side-effects-checkpoint-inhibitor-based-combination-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/emerging-problem-bacterial-resistance-cancer-patients-proceedings-workshop-held-mascc-neutropenia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/emerging-problem-bacterial-resistance-cancer-patients-proceedings-workshop-held-mascc-neutropenia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/emerging-problem-bacterial-resistance-cancer-patients-proceedings-workshop-held-mascc-neutropenia 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/nasopharyngeal-adenoid-cystic-carcinoma-rare-highly-challenging-disease-unmet-therapeutic-needs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/nasopharyngeal-adenoid-cystic-carcinoma-rare-highly-challenging-disease-unmet-therapeutic-needs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/nasopharyngeal-adenoid-cystic-carcinoma-rare-highly-challenging-disease-unmet-therapeutic-needs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/topography-mutational-processes-breast-cancer-genomes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/topography-mutational-processes-breast-cancer-genomes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/topography-mutational-processes-breast-cancer-genomes 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-study-prolactin-receptor-antagonist-lfa102-metastatic-breast-and-castration-resistant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-study-prolactin-receptor-antagonist-lfa102-metastatic-breast-and-castration-resistant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-study-prolactin-receptor-antagonist-lfa102-metastatic-breast-and-castration-resistant 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/missing-metastases-model-challenge-current-therapeutic-algorithms-colorectal-liver-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/missing-metastases-model-challenge-current-therapeutic-algorithms-colorectal-liver-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/missing-metastases-model-challenge-current-therapeutic-algorithms-colorectal-liver-metastases 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/results-belgian-expanded-access-program-eribulin-treatment-metastatic-breast-cancer-closely-mirror 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/results-belgian-expanded-access-program-eribulin-treatment-metastatic-breast-cancer-closely-mirror 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/results-belgian-expanded-access-program-eribulin-treatment-metastatic-breast-cancer-closely-mirror 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/too-little-benefit-too-much-toxicity-rethinking-adjuvant-development-model-colon-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/too-little-benefit-too-much-toxicity-rethinking-adjuvant-development-model-colon-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/too-little-benefit-too-much-toxicity-rethinking-adjuvant-development-model-colon-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/results-gamma-knife-radiosurgical-treatment-cerebral-arteriovenous-malformations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/results-gamma-knife-radiosurgical-treatment-cerebral-arteriovenous-malformations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/results-gamma-knife-radiosurgical-treatment-cerebral-arteriovenous-malformations 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/use-intraoperative-radiation-therapy-conservative-treatment-invasive-male-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/use-intraoperative-radiation-therapy-conservative-treatment-invasive-male-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/use-intraoperative-radiation-therapy-conservative-treatment-invasive-male-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/effects-estrogen-receptor-and-human-epidermal-growth-factor-receptor-2-levels-efficacy-trastuzumab 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effects-estrogen-receptor-and-human-epidermal-growth-factor-receptor-2-levels-efficacy-trastuzumab 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effects-estrogen-receptor-and-human-epidermal-growth-factor-receptor-2-levels-efficacy-trastuzumab 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-adjuvant-chemotherapy-older-breast-cancer-patients-clinical-and-biological-aging-parameters 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-adjuvant-chemotherapy-older-breast-cancer-patients-clinical-and-biological-aging-parameters 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-adjuvant-chemotherapy-older-breast-cancer-patients-clinical-and-biological-aging-parameters 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/managing-hodgkin-lymphoma-without-chemotherapy-novel-yet-welcomed-challenge 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/managing-hodgkin-lymphoma-without-chemotherapy-novel-yet-welcomed-challenge 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/managing-hodgkin-lymphoma-without-chemotherapy-novel-yet-welcomed-challenge 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/egfr-mutation-status-brain-metastases-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/egfr-mutation-status-brain-metastases-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/egfr-mutation-status-brain-metastases-non-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/landscape-somatic-mutations-560-breast-cancer-whole-genome-sequences 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/landscape-somatic-mutations-560-breast-cancer-whole-genome-sequences 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/landscape-somatic-mutations-560-breast-cancer-whole-genome-sequences 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/efficacy-and-safety-mitotane-treatment-adrenocortical-carcinoma-retrospective-study-34-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/efficacy-and-safety-mitotane-treatment-adrenocortical-carcinoma-retrospective-study-34-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/efficacy-and-safety-mitotane-treatment-adrenocortical-carcinoma-retrospective-study-34-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/monitoring-metabolic-response-using-fdg-pet-ct-during-targeted-therapy-metastatic-colorectal-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/monitoring-metabolic-response-using-fdg-pet-ct-during-targeted-therapy-metastatic-colorectal-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/monitoring-metabolic-response-using-fdg-pet-ct-during-targeted-therapy-metastatic-colorectal-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/it-possible-improve-communication-around-radiotherapy-delivery-randomized-study-assess-efficacy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/it-possible-improve-communication-around-radiotherapy-delivery-randomized-study-assess-efficacy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/it-possible-improve-communication-around-radiotherapy-delivery-randomized-study-assess-efficacy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/neratinib-plus-paclitaxel-vs-trastuzumab-plus-paclitaxel-previously-untreated-metastatic-erbb2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neratinib-plus-paclitaxel-vs-trastuzumab-plus-paclitaxel-previously-untreated-metastatic-erbb2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neratinib-plus-paclitaxel-vs-trastuzumab-plus-paclitaxel-previously-untreated-metastatic-erbb2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/corrigendum-implementation-geriatric-assessment-based-recommendations-older-patients-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/corrigendum-implementation-geriatric-assessment-based-recommendations-older-patients-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/corrigendum-implementation-geriatric-assessment-based-recommendations-older-patients-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/inequalities-lung-cancer-world-egfr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/inequalities-lung-cancer-world-egfr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/inequalities-lung-cancer-world-egfr 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bisphosphonate-related-osteonecrosis-jaw-review-potential-efficacy-low-level-laser-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bisphosphonate-related-osteonecrosis-jaw-review-potential-efficacy-low-level-laser-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bisphosphonate-related-osteonecrosis-jaw-review-potential-efficacy-low-level-laser-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/interval-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-first-line-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/interval-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-first-line-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/interval-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-first-line-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/learning-tsunami-immune-checkpoint-inhibitors-2015 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/learning-tsunami-immune-checkpoint-inhibitors-2015 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/learning-tsunami-immune-checkpoint-inhibitors-2015 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prospective-evaluation-first-line-erlotinib-advanced-non-small-cell-lung-cancer-nsclc-carrying 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prospective-evaluation-first-line-erlotinib-advanced-non-small-cell-lung-cancer-nsclc-carrying 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prospective-evaluation-first-line-erlotinib-advanced-non-small-cell-lung-cancer-nsclc-carrying 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prolonged-antiretroviral-therapy-associated-fewer-anal-high-grade-squamous-intraepithelial-lesions 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prolonged-antiretroviral-therapy-associated-fewer-anal-high-grade-squamous-intraepithelial-lesions 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prolonged-antiretroviral-therapy-associated-fewer-anal-high-grade-squamous-intraepithelial-lesions 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/intraocular-t-cell-lymphoma-clinical-presentation-diagnosis-treatment-and-outcome 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/intraocular-t-cell-lymphoma-clinical-presentation-diagnosis-treatment-and-outcome 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/intraocular-t-cell-lymphoma-clinical-presentation-diagnosis-treatment-and-outcome 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/fever-unknown-origin-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/fever-unknown-origin-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/fever-unknown-origin-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/impact-dermatologic-adverse-events-induced-targeted-therapies-quality-life 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-dermatologic-adverse-events-induced-targeted-therapies-quality-life 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-dermatologic-adverse-events-induced-targeted-therapies-quality-life 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/splenic-irradiation-hematopoietic-stem-cell-transplantation-chronic-myeloid-leukemia-long-term 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/splenic-irradiation-hematopoietic-stem-cell-transplantation-chronic-myeloid-leukemia-long-term 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/splenic-irradiation-hematopoietic-stem-cell-transplantation-chronic-myeloid-leukemia-long-term 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/non-randomized-dose-escalation-phase-i-trial-protein-based-immunotherapeutic-treatment-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/non-randomized-dose-escalation-phase-i-trial-protein-based-immunotherapeutic-treatment-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/non-randomized-dose-escalation-phase-i-trial-protein-based-immunotherapeutic-treatment-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/outcome-uterine-sarcoma-patients-treated-pazopanib-retrospective-analysis-based-two-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/outcome-uterine-sarcoma-patients-treated-pazopanib-retrospective-analysis-based-two-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/outcome-uterine-sarcoma-patients-treated-pazopanib-retrospective-analysis-based-two-european 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/glasgow-inflammatory-score-and-lung-cancer-predictor-admissions-emergency-units 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/glasgow-inflammatory-score-and-lung-cancer-predictor-admissions-emergency-units 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/glasgow-inflammatory-score-and-lung-cancer-predictor-admissions-emergency-units 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-chemotherapy-elderly-patients-breast-cancer-key-challenges 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-chemotherapy-elderly-patients-breast-cancer-key-challenges 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-chemotherapy-elderly-patients-breast-cancer-key-challenges 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/low-level-laser-therapyphotobiomodulation-management-side-effects-chemoradiation-therapy-head-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/low-level-laser-therapyphotobiomodulation-management-side-effects-chemoradiation-therapy-head-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/low-level-laser-therapyphotobiomodulation-management-side-effects-chemoradiation-therapy-head-and 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/express-approval-immune-checkpoint-inhibitors-conflict-between-science-and-finance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/express-approval-immune-checkpoint-inhibitors-conflict-between-science-and-finance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/express-approval-immune-checkpoint-inhibitors-conflict-between-science-and-finance 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/progression-free-survival-surrogate-endpoint-overall-survival-clinical-trials-her2-targeted-agents 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/progression-free-survival-surrogate-endpoint-overall-survival-clinical-trials-her2-targeted-agents 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/progression-free-survival-surrogate-endpoint-overall-survival-clinical-trials-her2-targeted-agents 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/squalene-epoxidase-bona-fide-oncogene-amplification-clinical-relevance-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/squalene-epoxidase-bona-fide-oncogene-amplification-clinical-relevance-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/squalene-epoxidase-bona-fide-oncogene-amplification-clinical-relevance-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/european-organisation-research-and-treatment-cancer-randomized-double-blind-placebo-controlled 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/european-organisation-research-and-treatment-cancer-randomized-double-blind-placebo-controlled 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/european-organisation-research-and-treatment-cancer-randomized-double-blind-placebo-controlled 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/why-balls-are-not-put-inside-basket-reflection-testicular-cancer-clinical-trial-design 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/why-balls-are-not-put-inside-basket-reflection-testicular-cancer-clinical-trial-design 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/why-balls-are-not-put-inside-basket-reflection-testicular-cancer-clinical-trial-design 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/breast-cancer-2015-academic-research-sheds-light-issues-matter-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/breast-cancer-2015-academic-research-sheds-light-issues-matter-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/breast-cancer-2015-academic-research-sheds-light-issues-matter-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/catalog-genetic-progression-human-cancers-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/catalog-genetic-progression-human-cancers-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/catalog-genetic-progression-human-cancers-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/oocytes-affected-smooth-endoplasmic-reticulum-aggregates-discard-or-not-discard 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/oocytes-affected-smooth-endoplasmic-reticulum-aggregates-discard-or-not-discard 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/oocytes-affected-smooth-endoplasmic-reticulum-aggregates-discard-or-not-discard 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunomodulatory-properties-human-bone-marrow-derived-mesenchymal-stromal-cells-are-defined 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immunomodulatory-properties-human-bone-marrow-derived-mesenchymal-stromal-cells-are-defined 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immunomodulatory-properties-human-bone-marrow-derived-mesenchymal-stromal-cells-are-defined 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/reply-letter-editor-esmo-magnitude-clinical-benefit-scaling-tool-theory-practice-hartmann-and-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/reply-letter-editor-esmo-magnitude-clinical-benefit-scaling-tool-theory-practice-hartmann-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/reply-letter-editor-esmo-magnitude-clinical-benefit-scaling-tool-theory-practice-hartmann-and-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/predictors-physicians-satisfaction-their-management-uncertainty-during-decision-making-encounter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/predictors-physicians-satisfaction-their-management-uncertainty-during-decision-making-encounter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/predictors-physicians-satisfaction-their-management-uncertainty-during-decision-making-encounter 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/predicting-microbiologically-defined-infection-febrile-neutropenic-episodes-children-global 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/predicting-microbiologically-defined-infection-febrile-neutropenic-episodes-children-global 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/predicting-microbiologically-defined-infection-febrile-neutropenic-episodes-children-global 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/1-3-ss-d-glucan-assay-diagnosing-invasive-fungal-infections-critically-ill-patients-hematological 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/1-3-ss-d-glucan-assay-diagnosing-invasive-fungal-infections-critically-ill-patients-hematological 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/1-3-ss-d-glucan-assay-diagnosing-invasive-fungal-infections-critically-ill-patients-hematological 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-characterization-primary-invasive-lobular-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-characterization-primary-invasive-lobular-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-characterization-primary-invasive-lobular-breast-cancer 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/improved-survival-calreticulin-mutated-patients-compared-janus-kinase-2-primary-myelofibrosis-meta 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improved-survival-calreticulin-mutated-patients-compared-janus-kinase-2-primary-myelofibrosis-meta 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improved-survival-calreticulin-mutated-patients-compared-janus-kinase-2-primary-myelofibrosis-meta 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/factors-associated-self-perceived-burden-primary-caregiver-older-patients-hematologic-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/factors-associated-self-perceived-burden-primary-caregiver-older-patients-hematologic-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/factors-associated-self-perceived-burden-primary-caregiver-older-patients-hematologic-malignancies 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/current-use-and-attitudes-towards-tumor-genome-sequencing-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/current-use-and-attitudes-towards-tumor-genome-sequencing-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/current-use-and-attitudes-towards-tumor-genome-sequencing-breast-cancer 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/helicale-tomotherapie-voor-de-behandeling-van-hoofd-halskanker 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/helicale-tomotherapie-voor-de-behandeling-van-hoofd-halskanker 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/helicale-tomotherapie-voor-de-behandeling-van-hoofd-halskanker 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/helicale-tomotherapie-de-behandeling-van-hoofd-halskanker-oncotherapie-nieuwsbrief-september-2015 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/helicale-tomotherapie-de-behandeling-van-hoofd-halskanker-oncotherapie-nieuwsbrief-september-2015 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/helicale-tomotherapie-de-behandeling-van-hoofd-halskanker-oncotherapie-nieuwsbrief-september-2015 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/iterative-and-prolonged-remission-metastatic-breast-cancer-using-pegylated-irinotecan-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/iterative-and-prolonged-remission-metastatic-breast-cancer-using-pegylated-irinotecan-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/iterative-and-prolonged-remission-metastatic-breast-cancer-using-pegylated-irinotecan-case-report 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/standardised-generic-validated-approach-stratify-magnitude-clinical-benefit-can-be-anticipated-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/standardised-generic-validated-approach-stratify-magnitude-clinical-benefit-can-be-anticipated-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/standardised-generic-validated-approach-stratify-magnitude-clinical-benefit-can-be-anticipated-0 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/gemcitabine-based-chemoradiation-treatment-locally-advanced-head-and-neck-cancer-systematic-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/gemcitabine-based-chemoradiation-treatment-locally-advanced-head-and-neck-cancer-systematic-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/gemcitabine-based-chemoradiation-treatment-locally-advanced-head-and-neck-cancer-systematic-review 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-optimal-combinations-modulation-factor-and-pitch-helical-tomotherapy-plans-made-tomoedge 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-optimal-combinations-modulation-factor-and-pitch-helical-tomotherapy-plans-made-tomoedge 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-optimal-combinations-modulation-factor-and-pitch-helical-tomotherapy-plans-made-tomoedge 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/fast-helical-tomotherapy-head-and-neck-cancer-planning-study-time-priceless 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/fast-helical-tomotherapy-head-and-neck-cancer-planning-study-time-priceless 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/fast-helical-tomotherapy-head-and-neck-cancer-planning-study-time-priceless 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/spurious-decrease-wbc-count-measured-wnr-channel-xn-haematology-analyser-sysmex-could-be-associated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/spurious-decrease-wbc-count-measured-wnr-channel-xn-haematology-analyser-sysmex-could-be-associated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/spurious-decrease-wbc-count-measured-wnr-channel-xn-haematology-analyser-sysmex-could-be-associated 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/time-trends-axilla-management-among-early-breast-cancer-patients-persisting-major-variation 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/time-trends-axilla-management-among-early-breast-cancer-patients-persisting-major-variation 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/time-trends-axilla-management-among-early-breast-cancer-patients-persisting-major-variation 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/vivo-characterizatio-blv-mirna-cluster 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/vivo-characterizatio-blv-mirna-cluster 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/vivo-characterizatio-blv-mirna-cluster 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/htlv-1blv-antisense-rna-dependent-host-gene-perturbation-pre-leukemic-and-leukemic-clones 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/htlv-1blv-antisense-rna-dependent-host-gene-perturbation-pre-leukemic-and-leukemic-clones 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/htlv-1blv-antisense-rna-dependent-host-gene-perturbation-pre-leukemic-and-leukemic-clones 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improving-methodology-detection-proviral-integration-sites-host-genome-high-throughput-sequencing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improving-methodology-detection-proviral-integration-sites-host-genome-high-throughput-sequencing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improving-methodology-detection-proviral-integration-sites-host-genome-high-throughput-sequencing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thiazole-derivatives-inhibitors-cyclooxygenases-vitro-and-vivo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thiazole-derivatives-inhibitors-cyclooxygenases-vitro-and-vivo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thiazole-derivatives-inhibitors-cyclooxygenases-vitro-and-vivo 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/classification-tnm-du-cancer-bronchique-ce-qui-pourrait-changer-en-2016-cours-du-groupe-d-oncologie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/classification-tnm-du-cancer-bronchique-ce-qui-pourrait-changer-en-2016-cours-du-groupe-d-oncologie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/classification-tnm-du-cancer-bronchique-ce-qui-pourrait-changer-en-2016-cours-du-groupe-d-oncologie 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/15eme-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/15eme-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/15eme-rencontre-eveline-markiewicz-sur-les-urgences-et-complications-severes-chez-le-patient 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/les-manques-l-integrite-scientifique-et-medicale 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/les-manques-l-integrite-scientifique-et-medicale 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/les-manques-l-integrite-scientifique-et-medicale 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/facteurs-pronostiques-et-cancers-bronchopulmonaires 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/facteurs-pronostiques-et-cancers-bronchopulmonaires 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/facteurs-pronostiques-et-cancers-bronchopulmonaires 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/new-metastases-are-associated-poorer-prognosis-growth-pre-existing-metastases-patients-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-metastases-are-associated-poorer-prognosis-growth-pre-existing-metastases-patients-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-metastases-are-associated-poorer-prognosis-growth-pre-existing-metastases-patients-metastatic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/thrombo-embolic-events-cancer-patients-impaired-renal-function 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/thrombo-embolic-events-cancer-patients-impaired-renal-function 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/thrombo-embolic-events-cancer-patients-impaired-renal-function 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/utility-next-generation-sequencing-cancer-drug-development-and-clinical-trials-next-generation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/utility-next-generation-sequencing-cancer-drug-development-and-clinical-trials-next-generation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/utility-next-generation-sequencing-cancer-drug-development-and-clinical-trials-next-generation 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/epidemiological-risk-factors-breast-cancer-premenopausal-women-maternal-medicine-2015-ebook-mcgraw 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/epidemiological-risk-factors-breast-cancer-premenopausal-women-maternal-medicine-2015-ebook-mcgraw 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/epidemiological-risk-factors-breast-cancer-premenopausal-women-maternal-medicine-2015-ebook-mcgraw 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/increased-body-mass-index-risk-factor-localized-prostate-cancer-treated-radical-prostatectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/increased-body-mass-index-risk-factor-localized-prostate-cancer-treated-radical-prostatectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/increased-body-mass-index-risk-factor-localized-prostate-cancer-treated-radical-prostatectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mesenchymal-stromal-cells-foreskin-tissue-isolation-cell-characterization-and-immunobiological 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/mesenchymal-stromal-cells-foreskin-tissue-isolation-cell-characterization-and-immunobiological 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/mesenchymal-stromal-cells-foreskin-tissue-isolation-cell-characterization-and-immunobiological 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/search-common-pathway-health-issues-men-sign-holmesian-deduction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/search-common-pathway-health-issues-men-sign-holmesian-deduction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/search-common-pathway-health-issues-men-sign-holmesian-deduction 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/abiraterone-acetate-post-docetaxel-metastatic-castration-resistant-prostate-cancer-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/abiraterone-acetate-post-docetaxel-metastatic-castration-resistant-prostate-cancer-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/abiraterone-acetate-post-docetaxel-metastatic-castration-resistant-prostate-cancer-belgian 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/imaging-diagnostic-and-therapeutic-targets-human-epidermal-growth-factor-receptor-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/imaging-diagnostic-and-therapeutic-targets-human-epidermal-growth-factor-receptor-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/imaging-diagnostic-and-therapeutic-targets-human-epidermal-growth-factor-receptor-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/identification-early-breast-cancer-patient-cohorts-who-may-benefit-lapatinib-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/identification-early-breast-cancer-patient-cohorts-who-may-benefit-lapatinib-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/identification-early-breast-cancer-patient-cohorts-who-may-benefit-lapatinib-therapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/afatinib-plus-vinorelbine-versus-trastuzumab-plus-vinorelbine-patients-her2-overexpressing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/afatinib-plus-vinorelbine-versus-trastuzumab-plus-vinorelbine-patients-her2-overexpressing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/afatinib-plus-vinorelbine-versus-trastuzumab-plus-vinorelbine-patients-her2-overexpressing 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunomodulatory-potential-mesenchymal-stromal-cells-story-regulatory-network 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immunomodulatory-potential-mesenchymal-stromal-cells-story-regulatory-network 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immunomodulatory-potential-mesenchymal-stromal-cells-story-regulatory-network 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/melanoma-specific-mhc-ii-expression-represents-tumour-autonomous-phenotype-and-predicts-response 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/melanoma-specific-mhc-ii-expression-represents-tumour-autonomous-phenotype-and-predicts-response 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/melanoma-specific-mhc-ii-expression-represents-tumour-autonomous-phenotype-and-predicts-response 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/cytotoxic-chemotherapy-still-mainstay-clinical-practice-all-subtypes-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cytotoxic-chemotherapy-still-mainstay-clinical-practice-all-subtypes-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cytotoxic-chemotherapy-still-mainstay-clinical-practice-all-subtypes-metastatic-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/innovative-perspectives-immunotherapy-head-and-neck-cancer-relevant-scientific-rationale-effective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/innovative-perspectives-immunotherapy-head-and-neck-cancer-relevant-scientific-rationale-effective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/innovative-perspectives-immunotherapy-head-and-neck-cancer-relevant-scientific-rationale-effective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/participation-italian-cancer-centres-alleanza-contro-il-cancro-acc-organisation-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/participation-italian-cancer-centres-alleanza-contro-il-cancro-acc-organisation-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/participation-italian-cancer-centres-alleanza-contro-il-cancro-acc-organisation-european-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/adapting-robotic-platform-small-operating-theaters-our-experience-side-docking-technique-robotic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adapting-robotic-platform-small-operating-theaters-our-experience-side-docking-technique-robotic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adapting-robotic-platform-small-operating-theaters-our-experience-side-docking-technique-robotic 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lymhoscintigraphy-and-other-imaging-methods-lymphedema-presentation-diagnosis-and-treatment-ak 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lymhoscintigraphy-and-other-imaging-methods-lymphedema-presentation-diagnosis-and-treatment-ak 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lymhoscintigraphy-and-other-imaging-methods-lymphedema-presentation-diagnosis-and-treatment-ak 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/multicentre-comparison-quantitative-90y-petct-dosimetric-purposes-after-radioembolization-resin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/multicentre-comparison-quantitative-90y-petct-dosimetric-purposes-after-radioembolization-resin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/multicentre-comparison-quantitative-90y-petct-dosimetric-purposes-after-radioembolization-resin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/circulating-tumor-cells-and-circulating-tumor-dna-challenges-and-opportunities-path-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/circulating-tumor-cells-and-circulating-tumor-dna-challenges-and-opportunities-path-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/circulating-tumor-cells-and-circulating-tumor-dna-challenges-and-opportunities-path-clinical 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/open-label-dose-escalation-study-evaluate-safety-and-pharmacokinetics-cep-9722-parp-1-and-parp-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/open-label-dose-escalation-study-evaluate-safety-and-pharmacokinetics-cep-9722-parp-1-and-parp-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/open-label-dose-escalation-study-evaluate-safety-and-pharmacokinetics-cep-9722-parp-1-and-parp-2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/impact-skin-toxicities-associated-targeted-cancer-therapies-body-image-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/impact-skin-toxicities-associated-targeted-cancer-therapies-body-image-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/impact-skin-toxicities-associated-targeted-cancer-therapies-body-image-prospective-study 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/mesenchymal-stromal-cells-and-immunomodulation-gathering-regulatory-immune-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/mesenchymal-stromal-cells-and-immunomodulation-gathering-regulatory-immune-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/mesenchymal-stromal-cells-and-immunomodulation-gathering-regulatory-immune-cells 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/difficulties-and-limitations-conducting-translational-research-thoracic-oncology-practical-example 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/difficulties-and-limitations-conducting-translational-research-thoracic-oncology-practical-example 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/difficulties-and-limitations-conducting-translational-research-thoracic-oncology-practical-example 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/p53-reactivation-prima-1-met-apr-246-sensitises-v600ek-braf-melanoma-vemurafenib 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/p53-reactivation-prima-1-met-apr-246-sensitises-v600ek-braf-melanoma-vemurafenib 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/p53-reactivation-prima-1-met-apr-246-sensitises-v600ek-braf-melanoma-vemurafenib 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/cancer-and-fertility-preservation-international-recommendations-expert-meeting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/cancer-and-fertility-preservation-international-recommendations-expert-meeting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/cancer-and-fertility-preservation-international-recommendations-expert-meeting 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/emerging-drugs-targeting-human-epidermal-growth-factor-receptor-2-her2-treatment-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/emerging-drugs-targeting-human-epidermal-growth-factor-receptor-2-her2-treatment-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/emerging-drugs-targeting-human-epidermal-growth-factor-receptor-2-her2-treatment-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/long-term-follow-eortc-18952-trial-adjuvant-therapy-resected-stage-iib-iii-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-term-follow-eortc-18952-trial-adjuvant-therapy-resected-stage-iib-iii-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-term-follow-eortc-18952-trial-adjuvant-therapy-resected-stage-iib-iii-cutaneous-melanoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/improved-treatment-breast-cancer-anti-her2-therapy-requires-interleukin-21-signaling-cd8-t-cells 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/improved-treatment-breast-cancer-anti-her2-therapy-requires-interleukin-21-signaling-cd8-t-cells 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/improved-treatment-breast-cancer-anti-her2-therapy-requires-interleukin-21-signaling-cd8-t-cells 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-ii-study-necitumumab-plus-modified-folfox6-first-line-treatment-patients-locally-advanced-or 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-ii-study-necitumumab-plus-modified-folfox6-first-line-treatment-patients-locally-advanced-or 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-ii-study-necitumumab-plus-modified-folfox6-first-line-treatment-patients-locally-advanced-or 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/critical-analysis-early-recurrences-after-laparoscopic-radical-cystectomy-large-cohort-esut-we-must 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/critical-analysis-early-recurrences-after-laparoscopic-radical-cystectomy-large-cohort-esut-we-must 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/critical-analysis-early-recurrences-after-laparoscopic-radical-cystectomy-large-cohort-esut-we-must 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/role-corticosteroids-prostate-cancer-progression-implications-treatment-strategy-metastatic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/role-corticosteroids-prostate-cancer-progression-implications-treatment-strategy-metastatic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/role-corticosteroids-prostate-cancer-progression-implications-treatment-strategy-metastatic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/results-comparative-analysis-magnetic-resonance-imaging-targeted-versus-three-dimensional 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/results-comparative-analysis-magnetic-resonance-imaging-targeted-versus-three-dimensional 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/results-comparative-analysis-magnetic-resonance-imaging-targeted-versus-three-dimensional 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/long-acting-octreotide-secondary-prevention-chemotherapy-induced-diarrhea-proof-concept 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/long-acting-octreotide-secondary-prevention-chemotherapy-induced-diarrhea-proof-concept 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/long-acting-octreotide-secondary-prevention-chemotherapy-induced-diarrhea-proof-concept 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/belgian-survey-geriatric-assessment-oncology-focusing-large-scale-implementation-and-related 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/belgian-survey-geriatric-assessment-oncology-focusing-large-scale-implementation-and-related 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/belgian-survey-geriatric-assessment-oncology-focusing-large-scale-implementation-and-related 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/discordant-assessment-tumor-biomarkers-histopathological-and-molecular-assays-eortc-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/discordant-assessment-tumor-biomarkers-histopathological-and-molecular-assays-eortc-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/discordant-assessment-tumor-biomarkers-histopathological-and-molecular-assays-eortc-randomized 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/unknown-primary-tumors-there-future-therapeutic-role-immune-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/unknown-primary-tumors-there-future-therapeutic-role-immune-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/unknown-primary-tumors-there-future-therapeutic-role-immune-checkpoint-inhibitors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/emerging-strategies-managing-differentiated-thyroid-cancers-refractory-radioiodine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/emerging-strategies-managing-differentiated-thyroid-cancers-refractory-radioiodine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/emerging-strategies-managing-differentiated-thyroid-cancers-refractory-radioiodine 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bev-ip-perioperative-chemotherapy-bevacizumab-patients-undergoing-cytoreduction-and-intraperitoneal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bev-ip-perioperative-chemotherapy-bevacizumab-patients-undergoing-cytoreduction-and-intraperitoneal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bev-ip-perioperative-chemotherapy-bevacizumab-patients-undergoing-cytoreduction-and-intraperitoneal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/isavuconazole-versus-voriconazole-primary-treatment-invasive-mould-disease-caused-aspergillus-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/isavuconazole-versus-voriconazole-primary-treatment-invasive-mould-disease-caused-aspergillus-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/isavuconazole-versus-voriconazole-primary-treatment-invasive-mould-disease-caused-aspergillus-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lower-urinary-tract-dysfunction-following-nerve-sparing-radical-hysterectomy-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lower-urinary-tract-dysfunction-following-nerve-sparing-radical-hysterectomy-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lower-urinary-tract-dysfunction-following-nerve-sparing-radical-hysterectomy-systematic-review 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/trastuzumab-re-treatment-following-adjuvant-trastuzumab-and-importance-distant-disease-free 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/trastuzumab-re-treatment-following-adjuvant-trastuzumab-and-importance-distant-disease-free 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/trastuzumab-re-treatment-following-adjuvant-trastuzumab-and-importance-distant-disease-free 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-quantitative-polymerase-chain-reaction-markers-detection-breast-cancer-cells-ovarian 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-quantitative-polymerase-chain-reaction-markers-detection-breast-cancer-cells-ovarian 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-quantitative-polymerase-chain-reaction-markers-detection-breast-cancer-cells-ovarian 2024-05-05T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/ambulatory-outpatient-management-patients-low-risk-febrile-neutropaenia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ambulatory-outpatient-management-patients-low-risk-febrile-neutropaenia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ambulatory-outpatient-management-patients-low-risk-febrile-neutropaenia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/high-risk-human-papillomavirus-genotypes-distribution-cohort-hiv-positive-women-living-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-risk-human-papillomavirus-genotypes-distribution-cohort-hiv-positive-women-living-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-risk-human-papillomavirus-genotypes-distribution-cohort-hiv-positive-women-living-europe 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/menopausal-hormone-therapy-use-relation-breast-cancer-incidence-11-european-countries 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/menopausal-hormone-therapy-use-relation-breast-cancer-incidence-11-european-countries 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/menopausal-hormone-therapy-use-relation-breast-cancer-incidence-11-european-countries 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/clinical-relevance-host-immunity-breast-cancer-tils-clinic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/clinical-relevance-host-immunity-breast-cancer-tils-clinic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/clinical-relevance-host-immunity-breast-cancer-tils-clinic 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/near-infrared-fluorescent-imaging-after-intravenous-injection-indocyanine-green-during-neck 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/near-infrared-fluorescent-imaging-after-intravenous-injection-indocyanine-green-during-neck 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/near-infrared-fluorescent-imaging-after-intravenous-injection-indocyanine-green-during-neck 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/response-it-safe-perform-controlled-ovarian-stimulation-assisted-reproduction-young-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/response-it-safe-perform-controlled-ovarian-stimulation-assisted-reproduction-young-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/response-it-safe-perform-controlled-ovarian-stimulation-assisted-reproduction-young-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/should-treatment-advanced-lepidic-adenocarcinoma-be-adapted-pathological-subtype 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/should-treatment-advanced-lepidic-adenocarcinoma-be-adapted-pathological-subtype 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/should-treatment-advanced-lepidic-adenocarcinoma-be-adapted-pathological-subtype 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/targeted-therapy-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/targeted-therapy-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/targeted-therapy-lung-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/health-impacts-anthropogenic-biomass-burning-developed-world 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/health-impacts-anthropogenic-biomass-burning-developed-world 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/health-impacts-anthropogenic-biomass-burning-developed-world 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/primary-tumour-standardised-uptake-value-prognostic-nonsmall-cell-lung-cancer-multivariate-pooled 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/primary-tumour-standardised-uptake-value-prognostic-nonsmall-cell-lung-cancer-multivariate-pooled 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/primary-tumour-standardised-uptake-value-prognostic-nonsmall-cell-lung-cancer-multivariate-pooled 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/gorham-stout-disease-proximal-fibula-treated-radiotherapy-and-zoledronic-acid 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/gorham-stout-disease-proximal-fibula-treated-radiotherapy-and-zoledronic-acid 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/gorham-stout-disease-proximal-fibula-treated-radiotherapy-and-zoledronic-acid 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/rasmapk-activation-associated-reduced-tumor-infiltrating-lymphocytes-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/rasmapk-activation-associated-reduced-tumor-infiltrating-lymphocytes-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/rasmapk-activation-associated-reduced-tumor-infiltrating-lymphocytes-triple-negative-breast-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/circulating-free-dna-new-dynamic-marker-nonsmall-cell-lung-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/circulating-free-dna-new-dynamic-marker-nonsmall-cell-lung-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/circulating-free-dna-new-dynamic-marker-nonsmall-cell-lung-cancer-patients 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prognostic-significance-metabolic-response-heterogeneity-metastatic-colorectal-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/prognostic-significance-metabolic-response-heterogeneity-metastatic-colorectal-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/prognostic-significance-metabolic-response-heterogeneity-metastatic-colorectal-cancer 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/current-management-marginal-zone-lymphomas 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/current-management-marginal-zone-lymphomas 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/current-management-marginal-zone-lymphomas 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/implementation-oncological-care-program-multidisciplinary-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/implementation-oncological-care-program-multidisciplinary-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/implementation-oncological-care-program-multidisciplinary-clinic 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/evolution-therapeutic-strategy-localized-resectable-pancreatic-ductal-adenocarcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evolution-therapeutic-strategy-localized-resectable-pancreatic-ductal-adenocarcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evolution-therapeutic-strategy-localized-resectable-pancreatic-ductal-adenocarcinoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/health-related-quality-life-patients-locally-advanced-or-metastatic-breast-cancer-treated-eribulin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/health-related-quality-life-patients-locally-advanced-or-metastatic-breast-cancer-treated-eribulin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/health-related-quality-life-patients-locally-advanced-or-metastatic-breast-cancer-treated-eribulin 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/prospective-clinical-trial-hifu-hemiablation-clinically-localized-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prospective-clinical-trial-hifu-hemiablation-clinically-localized-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prospective-clinical-trial-hifu-hemiablation-clinically-localized-prostate-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/ccr-20th-anniversary-commentary-gene-expression-signature-breast-cancer-where-did-it-start-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/ccr-20th-anniversary-commentary-gene-expression-signature-breast-cancer-where-did-it-start-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/ccr-20th-anniversary-commentary-gene-expression-signature-breast-cancer-where-did-it-start-and 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/etirinotecan-pegol-nktr-102-versus-treatment-physician-s-choice-women-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/etirinotecan-pegol-nktr-102-versus-treatment-physician-s-choice-women-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/etirinotecan-pegol-nktr-102-versus-treatment-physician-s-choice-women-advanced-breast-cancer 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/acute-respiratory-failure-patients-hematological-malignancies-outcomes-according-initial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/acute-respiratory-failure-patients-hematological-malignancies-outcomes-according-initial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/acute-respiratory-failure-patients-hematological-malignancies-outcomes-according-initial 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/idarubicin-and-cytarabine-combination-gemtuzumab-ozogamicin-iago-untreated-patients-high-risk-mds 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/idarubicin-and-cytarabine-combination-gemtuzumab-ozogamicin-iago-untreated-patients-high-risk-mds 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/idarubicin-and-cytarabine-combination-gemtuzumab-ozogamicin-iago-untreated-patients-high-risk-mds 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/adjuvant-lapatinib-and-trastuzumab-early-human-epidermal-growth-factor-receptor-2-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/adjuvant-lapatinib-and-trastuzumab-early-human-epidermal-growth-factor-receptor-2-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/adjuvant-lapatinib-and-trastuzumab-early-human-epidermal-growth-factor-receptor-2-positive-breast 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/acute-kidney-injury-critically-ill-patients-haematological-malignancies-results-multicentre-cohort 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/acute-kidney-injury-critically-ill-patients-haematological-malignancies-results-multicentre-cohort 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/acute-kidney-injury-critically-ill-patients-haematological-malignancies-results-multicentre-cohort 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/does-multimedia-education-3d-animation-impact-quality-and-duration-urologists-interactions-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/does-multimedia-education-3d-animation-impact-quality-and-duration-urologists-interactions-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/does-multimedia-education-3d-animation-impact-quality-and-duration-urologists-interactions-their 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/checkpoint-inhibitors-bladder-and-renal-cancers-results-and-perspectives 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/checkpoint-inhibitors-bladder-and-renal-cancers-results-and-perspectives 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/checkpoint-inhibitors-bladder-and-renal-cancers-results-and-perspectives 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/new-global-analysis-microrna-transcriptome-primary-tumors-and-lymph-node-metastases-papillary 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/new-global-analysis-microrna-transcriptome-primary-tumors-and-lymph-node-metastases-papillary 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/new-global-analysis-microrna-transcriptome-primary-tumors-and-lymph-node-metastases-papillary 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/approach-and-complications-associated-suburethral-synthetic-slings-women-systematic-review-and-meta 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/approach-and-complications-associated-suburethral-synthetic-slings-women-systematic-review-and-meta 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/approach-and-complications-associated-suburethral-synthetic-slings-women-systematic-review-and-meta 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/novel-mechanisms-and-approaches-medical-therapy-solid-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/novel-mechanisms-and-approaches-medical-therapy-solid-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/novel-mechanisms-and-approaches-medical-therapy-solid-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lower-urinary-tract-dysfunction-following-radical-hysterectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lower-urinary-tract-dysfunction-following-radical-hysterectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lower-urinary-tract-dysfunction-following-radical-hysterectomy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/micrornas-regulate-kdm5-histone-demethylases-breast-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/micrornas-regulate-kdm5-histone-demethylases-breast-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/micrornas-regulate-kdm5-histone-demethylases-breast-cancer-cells 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/bladder-sparing-robot-assisted-laparoscopic-en-bloc-resection-urachus-and-umbilicus-urachal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/bladder-sparing-robot-assisted-laparoscopic-en-bloc-resection-urachus-and-umbilicus-urachal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/bladder-sparing-robot-assisted-laparoscopic-en-bloc-resection-urachus-and-umbilicus-urachal 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/euthanasia-2002-2014-situation-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/euthanasia-2002-2014-situation-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/euthanasia-2002-2014-situation-belgium 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-aberrations-young-and-elderly-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-aberrations-young-and-elderly-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-aberrations-young-and-elderly-breast-cancer-patients 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/head-docking-single-stage-robotic-cortical-sparing-adrenalectomy-bilateral-pheochromocytoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/head-docking-single-stage-robotic-cortical-sparing-adrenalectomy-bilateral-pheochromocytoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/head-docking-single-stage-robotic-cortical-sparing-adrenalectomy-bilateral-pheochromocytoma 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/liquid-biopsy-will-it-be-magic-tool-monitoring-response-solid-tumors-anticancer-therapies 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/liquid-biopsy-will-it-be-magic-tool-monitoring-response-solid-tumors-anticancer-therapies 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/liquid-biopsy-will-it-be-magic-tool-monitoring-response-solid-tumors-anticancer-therapies 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/high-intensity-focused-ultrasound-versus-brachytherapy-treatment-localized-prostate-cancer-matched 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/high-intensity-focused-ultrasound-versus-brachytherapy-treatment-localized-prostate-cancer-matched 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/high-intensity-focused-ultrasound-versus-brachytherapy-treatment-localized-prostate-cancer-matched 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/practical-approach-lymphomas-major-role-general-practitioner-who-has-face-all-these-emerging-drugs 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/practical-approach-lymphomas-major-role-general-practitioner-who-has-face-all-these-emerging-drugs 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/practical-approach-lymphomas-major-role-general-practitioner-who-has-face-all-these-emerging-drugs 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/colorectal-cancer-ten-years-illusion-progress-advances-are-horizon 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/colorectal-cancer-ten-years-illusion-progress-advances-are-horizon 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/colorectal-cancer-ten-years-illusion-progress-advances-are-horizon 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/supportivepalliative-care-cancer-patients-quo-vadis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/supportivepalliative-care-cancer-patients-quo-vadis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/supportivepalliative-care-cancer-patients-quo-vadis 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/neoadjuvant-chemotherapy-and-trastuzumab-versus-neoadjuvant-chemotherapy-followed-post-operative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/neoadjuvant-chemotherapy-and-trastuzumab-versus-neoadjuvant-chemotherapy-followed-post-operative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/neoadjuvant-chemotherapy-and-trastuzumab-versus-neoadjuvant-chemotherapy-followed-post-operative 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/how-do-patient-perceived-determinants-influence-decision-making-process-accept-or-decline 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/how-do-patient-perceived-determinants-influence-decision-making-process-accept-or-decline 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/how-do-patient-perceived-determinants-influence-decision-making-process-accept-or-decline 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/will-modern-immunotherapies-become-standard-care-advanced-synchronous-or-metachronous-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/will-modern-immunotherapies-become-standard-care-advanced-synchronous-or-metachronous-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/will-modern-immunotherapies-become-standard-care-advanced-synchronous-or-metachronous-cancers 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/integrative-proteomic-and-gene-expression-analysis-identify-potential-biomarkers-adjuvant 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/integrative-proteomic-and-gene-expression-analysis-identify-potential-biomarkers-adjuvant 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/integrative-proteomic-and-gene-expression-analysis-identify-potential-biomarkers-adjuvant 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/genomic-grade-assay-compared-ki67-determine-risk-distant-breast-cancer-recurrence 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/genomic-grade-assay-compared-ki67-determine-risk-distant-breast-cancer-recurrence 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/genomic-grade-assay-compared-ki67-determine-risk-distant-breast-cancer-recurrence 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/repeat-gamma-knife-surgery-vestibular-schwannomas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/repeat-gamma-knife-surgery-vestibular-schwannomas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/repeat-gamma-knife-surgery-vestibular-schwannomas 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/principles-governing-i-rna-editing-breast-cancer-transcriptome 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/principles-governing-i-rna-editing-breast-cancer-transcriptome 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/principles-governing-i-rna-editing-breast-cancer-transcriptome 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/radioembolisation-and-portal-vein-embolization-resection-large-hepatocellular-carcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/radioembolisation-and-portal-vein-embolization-resection-large-hepatocellular-carcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/radioembolisation-and-portal-vein-embolization-resection-large-hepatocellular-carcinoma 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/correlative-analysis-genetic-alterations-and-everolimus-benefit-hormone-receptor-positive-human 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/correlative-analysis-genetic-alterations-and-everolimus-benefit-hormone-receptor-positive-human 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/correlative-analysis-genetic-alterations-and-everolimus-benefit-hormone-receptor-positive-human 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/benefit-neoadjuvant-anti-human-epidermal-growth-factor-receptor-2-her2-targeted-therapies-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/benefit-neoadjuvant-anti-human-epidermal-growth-factor-receptor-2-her2-targeted-therapies-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/benefit-neoadjuvant-anti-human-epidermal-growth-factor-receptor-2-her2-targeted-therapies-her2 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/joint-model-dependence-between-clustered-times-tumour-progression-and-deaths-meta-analysis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/joint-model-dependence-between-clustered-times-tumour-progression-and-deaths-meta-analysis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/joint-model-dependence-between-clustered-times-tumour-progression-and-deaths-meta-analysis 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/cardiac-assessment-early-breast-cancer-patients-18years-after-treatment-cyclophosphamide 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/cardiac-assessment-early-breast-cancer-patients-18years-after-treatment-cyclophosphamide 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/cardiac-assessment-early-breast-cancer-patients-18years-after-treatment-cyclophosphamide 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/characterization-human-breast-cancer-tissues-infrared-imaging 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/characterization-human-breast-cancer-tissues-infrared-imaging 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/characterization-human-breast-cancer-tissues-infrared-imaging 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/paget-bone-disease-demonstrated-68ga-psma-ligand-petct 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/paget-bone-disease-demonstrated-68ga-psma-ligand-petct 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/paget-bone-disease-demonstrated-68ga-psma-ligand-petct 2024-04-14T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/phase-i-study-two-dosing-schedules-oral-bi-847325-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/phase-i-study-two-dosing-schedules-oral-bi-847325-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/phase-i-study-two-dosing-schedules-oral-bi-847325-patients-advanced-solid-tumors 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/ovarian-suppression-using-luteinizing-hormone-releasing-hormone-agonists-during-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/ovarian-suppression-using-luteinizing-hormone-releasing-hormone-agonists-during-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/ovarian-suppression-using-luteinizing-hormone-releasing-hormone-agonists-during-chemotherapy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/what-can-be-learned-our-pediatric-colleagues 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/what-can-be-learned-our-pediatric-colleagues 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/what-can-be-learned-our-pediatric-colleagues 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/immunology-and-breast-cancer-toward-new-way-understanding-breast-cancer-and-developing-novel 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/immunology-and-breast-cancer-toward-new-way-understanding-breast-cancer-and-developing-novel 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/immunology-and-breast-cancer-toward-new-way-understanding-breast-cancer-and-developing-novel 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/message-ers-president-and-ers-secretary-eu-affairs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/message-ers-president-and-ers-secretary-eu-affairs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/message-ers-president-and-ers-secretary-eu-affairs 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/quantitative-dce-mri-prediction-pathological-complete-response-following-neoadjuvant-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/quantitative-dce-mri-prediction-pathological-complete-response-following-neoadjuvant-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/quantitative-dce-mri-prediction-pathological-complete-response-following-neoadjuvant-treatment 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/effect-noninvasive-ventilation-vs-oxygen-therapy-mortality-among-immunocompromised-patients-acute 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/effect-noninvasive-ventilation-vs-oxygen-therapy-mortality-among-immunocompromised-patients-acute 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/effect-noninvasive-ventilation-vs-oxygen-therapy-mortality-among-immunocompromised-patients-acute 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/lung-cancer-screening-white-paper-slippery-step-forward 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/lung-cancer-screening-white-paper-slippery-step-forward 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/lung-cancer-screening-white-paper-slippery-step-forward 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/minimally-invasive-devices-treating-lower-urinary-tract-symptoms-benign-prostate-hyperplasia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/minimally-invasive-devices-treating-lower-urinary-tract-symptoms-benign-prostate-hyperplasia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/minimally-invasive-devices-treating-lower-urinary-tract-symptoms-benign-prostate-hyperplasia 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/molecular-imaging-tool-investigate-heterogeneity-advanced-her2-positive-breast-cancer-and-predict 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/molecular-imaging-tool-investigate-heterogeneity-advanced-her2-positive-breast-cancer-and-predict 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/molecular-imaging-tool-investigate-heterogeneity-advanced-her2-positive-breast-cancer-and-predict 2024-03-03T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/next-revolution-molecular-theranostics-personalized-medicine-urologic-cancers 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/next-revolution-molecular-theranostics-personalized-medicine-urologic-cancers 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/next-revolution-molecular-theranostics-personalized-medicine-urologic-cancers 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/novel-double-mutation-val648ile-and-val804leu-ret-proto-oncogene-multiple-endocrine-neoplasia-type 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/novel-double-mutation-val648ile-and-val804leu-ret-proto-oncogene-multiple-endocrine-neoplasia-type 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/novel-double-mutation-val648ile-and-val804leu-ret-proto-oncogene-multiple-endocrine-neoplasia-type 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/optimal-adjuvant-treatment-patients-her2-positive-breast-cancer-2015 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/optimal-adjuvant-treatment-patients-her2-positive-breast-cancer-2015 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/optimal-adjuvant-treatment-patients-her2-positive-breast-cancer-2015 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/evaluation-targeted-therapies-advanced-breast-cancer-need-large-scale-molecular-screening-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/evaluation-targeted-therapies-advanced-breast-cancer-need-large-scale-molecular-screening-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/evaluation-targeted-therapies-advanced-breast-cancer-need-large-scale-molecular-screening-and 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/pregnancy-following-breast-cancer-using-assisted-reproduction-and-its-effect-long-term-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/pregnancy-following-breast-cancer-using-assisted-reproduction-and-its-effect-long-term-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/pregnancy-following-breast-cancer-using-assisted-reproduction-and-its-effect-long-term-outcome 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/exploring-safety-chemotherapy-treating-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/exploring-safety-chemotherapy-treating-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/exploring-safety-chemotherapy-treating-breast-cancer-during-pregnancy 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/disappearance-upper-urinary-tract-urothelial-carcinoma-after-treatment-borderline-brenner-tumor 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/disappearance-upper-urinary-tract-urothelial-carcinoma-after-treatment-borderline-brenner-tumor 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/disappearance-upper-urinary-tract-urothelial-carcinoma-after-treatment-borderline-brenner-tumor 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/comparison-between-home-and-hospital-set-unattended-home-based-polysomnography-prospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/comparison-between-home-and-hospital-set-unattended-home-based-polysomnography-prospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/comparison-between-home-and-hospital-set-unattended-home-based-polysomnography-prospective 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/international-study-increase-concordance-ki67-scoring 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/international-study-increase-concordance-ki67-scoring 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/international-study-increase-concordance-ki67-scoring 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/chest-radiation-now-classical-practice-extensive-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/chest-radiation-now-classical-practice-extensive-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/chest-radiation-now-classical-practice-extensive-small-cell-lung-cancer 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/st-gallen-international-expert-consensus-primary-therapy-early-breast-cancer-invaluable-tool 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/st-gallen-international-expert-consensus-primary-therapy-early-breast-cancer-invaluable-tool 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/st-gallen-international-expert-consensus-primary-therapy-early-breast-cancer-invaluable-tool 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/reactivation-multipotency-oncogenic-pik3ca-induces-breast-tumour-heterogeneity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/reactivation-multipotency-oncogenic-pik3ca-induces-breast-tumour-heterogeneity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/reactivation-multipotency-oncogenic-pik3ca-induces-breast-tumour-heterogeneity 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/smoking-control-priority-promote-heart-lung-blood-and-sleep-health 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/smoking-control-priority-promote-heart-lung-blood-and-sleep-health 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/smoking-control-priority-promote-heart-lung-blood-and-sleep-health 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/fluorescence-imaging-after-intraoperative-intravenous-injection-indocyanine-green-detection-lymph 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/fr/fluorescence-imaging-after-intraoperative-intravenous-injection-indocyanine-green-detection-lymph 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/nl/fluorescence-imaging-after-intraoperative-intravenous-injection-indocyanine-green-detection-lymph 2024-03-10T07:00:03+01:00 0.5 https://bordet.makemeweb.dev/en/prospective-observational-grouped-analysis-evaluate-effect-triptorelin-lower-urinary-tract-symptoms 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/prospective-observational-grouped-analysis-evaluate-effect-triptorelin-lower-urinary-tract-symptoms 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/prospective-observational-grouped-analysis-evaluate-effect-triptorelin-lower-urinary-tract-symptoms 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/retrospective-rescreening-negative-cervical-cytology-samples-preceding-histologically-proven-cin2-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/retrospective-rescreening-negative-cervical-cytology-samples-preceding-histologically-proven-cin2-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/retrospective-rescreening-negative-cervical-cytology-samples-preceding-histologically-proven-cin2-3 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/real-time-vivo-microscopic-imaging-cervix-using-confocal-laser-endomicroscopy-preliminary 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/fr/real-time-vivo-microscopic-imaging-cervix-using-confocal-laser-endomicroscopy-preliminary 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/nl/real-time-vivo-microscopic-imaging-cervix-using-confocal-laser-endomicroscopy-preliminary 2024-04-21T07:00:04+02:00 0.5 https://bordet.makemeweb.dev/en/constitutive-phosphorylated-stat3-associated-gene-signature-predictive-trastuzumab-resistance 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/constitutive-phosphorylated-stat3-associated-gene-signature-predictive-trastuzumab-resistance 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/constitutive-phosphorylated-stat3-associated-gene-signature-predictive-trastuzumab-resistance 2024-03-31T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/en/final-10-year-results-breast-international-group-2-98-phase-iii-trial-and-role-ki67-predicting 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/fr/final-10-year-results-breast-international-group-2-98-phase-iii-trial-and-role-ki67-predicting 2024-04-28T07:00:03+02:00 0.5 https://bordet.makemeweb.dev/nl/final-10-year-results-breast-international-group-2-98-phase-iii-trial-and-role-ki67-predicting 2024-04-28T07:00:03+02:00 0.5